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EXECUTIVE SUMMARY 
___________________________________________________________________
___ 
 
This study was prompted by the growing interest in and demand for non-opiate 
alternatives to methadone detoxification, such as the 2-adrenergic agonist 
lofexidine.  
Lofexidine acts centrally to suppress the opiate withdrawal syndrome and offers a 
non-opiate, rapid withdrawal treatment from opiates, without the risk of 
dependency. The study aims to identify an appropriate alternative model for a 
Community Detoxification Team for implementation in Clondalkin, an urban area 
where there are high levels of opiate misuse. 
 
The review of the relevant literature provided a conceptual and practical base of 
knowledge to inform the study. The review found that lofexidine can be used safely 
in a community stetting and therefore could provide a viable, safe alternative to 
methadone.  
 
Qualitative research techniques were employed to illicit key informants’ experiences 
and views of lofexidine detoxification. 20 people participated in two focus groups, 
while 11 participated in individual semi-structured interviews. Interviews were 
transcribed and analysis aided by the use of the Nud*ist 4 software package.  
 
The findings of this study support the need for the provision of alternative treatment 
options to drug misuser. In general, lofexidine was found to be suitable mainly for 
younger users with a short history of opiate dependence. Motivation, family and 
social supports together with the availability of counselling were identified as 
important factors in determining a positive outcome from lofexidine detoxification. 
 
The study recommends that a Community Detoxification Team, using lofexidine, be 
established on a pilot basis. The team should consist of a Co-ordinator, Drugs 
Worker, Nurse and General Practitioner. It is proposed that the community 
detoxification programme will take place over a four-week period and an integrated 
care pathway has been identified. Areas of further research were also discussed. 
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CHPATER ONE 
 
INTRODUCTION 
___________________________________________________________________
___ 
 
1.1 Introduction 
 
The aim of this study is to identify an appropriate alternative model for a 
Community Detoxification Team for implementation in Clondalkin, an urban area 
where there are high levels of opiate misuse. 
 
Drug misuse, particularly opiate misuse, remains one of the major social problems 
facing Irish society today. A recent capture recapture study of the prevalence of 
opiate use in Ireland 2000-2001 (Kelly et al, 2003) showed an overall prevalence of 
opiate1 use of 5.6/1,000 population. Males aged 25-34 years had a higher national 
prevalence (13.7 and 14.7/1,000 pop for 2000 and 2001) compared with the 
remaining males and females of all ages. 
 
Dependence on opioid1 drugs is a major health and social issue in most societies. 
Although the prevalence of opioid use is low, the burden of disease is substantial. 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2003) 
indicates that in the European Union around two percent of the general population 
has ever used opioids for non-medical purposes. The burden to the individual user 
and the community of opioid dependence arises from mortality (National Institutes 
of Health, 1997), which is most marked in the 15 to 34 year age group (Hall, 1998), 
transmission of HIV and hepatitis C, health care costs, crime and law enforcement 
costs, as well as the less tangible costs of family disruption and lost productivity 
(Mark, 2001).  
 
                                                
1 Opiates/ Opioids: the terms refer to a group of alkaloids derived from the opium poppy with the 
capacity to reduce pain and produce a sense of well being (euphoria), and, in higher doses, stupor, 
coma, and respiratory depression. The terms include both natural and synthetic opioids such as, 
heroin and methadone 
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Treatment is central to the reduction of the harms incurred by individuals and the 
community from opioid dependence. In fact, there is strong evidence to show that 
treatment programmes are able to confer important benefits on drug misusers, their 
families and the wider community and society (United Nations International Drug 
Control Programme, 2003). Treatment can be defined in general terms as the 
provision of one or more structured interventions designed to manage health and 
other problems as a consequence of drug misuse and to improve or maximise 
personal and social functioning. 
 
Managed withdrawal, or detoxification, is not in itself a treatment for dependence 
(Mattick, 1996). Rates of completion of withdrawal tend to be low, and rates of 
relapse to opioid use following detoxification are high (Broers et al, 2000; Gossop et 
al, 1989), but withdrawal remains a required first step for many forms of longer-
term treatment (Kleber et al, 1982). It may also represent the end point of an 
extensive period of substitution treatment such as methadone2 maintenance. As 
such, the availability of managed withdrawal is essential to an effective and 
comprehensive treatment system. 
 
 
1.2 Overview and Objectives of Study 
 
The aim of this study is to identify an appropriate alternative model for a 
Community Detoxification Team for implementation in Clondalkin, an urban area 
where there are high levels of opiate misuse. Currently the most widely used 
treatment modality for detoxification involves suppression of withdrawal from 
opiates with methadone and gradual reduction of the methadone dose over a period 
of time, usually twelve to fourteen weeks. I propose to carry out this study by 
researching key informants’ experiences of lofexidine detoxification. Lofexidine is a 
non-opioid 2-adrenergic agonist, which has been found to suppress the chemicals 
which produce the acute withdrawal symptoms drug misusers experience when they 
are undergoing detoxification from opiates. 
The objectives of the study include: 
                                                
2 Methadone is a synthetic opiate drug, which when given in an adequate dose to opiate dependent 
individuals it reduces the desire to use heroin and other opiates, eliminates opioid withdrawal, and 
blocks the euphoric effects of the other opioid drugs 
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1. To document the nature and extent of existing non-methadone based 
detoxification services using the 2-adrenergic agonist lofexidine; 
2. To identify a range of models of good practice at local, national and 
international level; 
3. To identify appropriate protocols in which a Community Detoxification 
Team should operate; and 
4. To identify an appropriate operational model for a Community 
Detoxification Team, taking account of the current structure of health care 
delivery in Ireland 
 
The research achieves these aims and objectives through qualitative research 
methods, in which 20 people participated in two focus groups, while 11 participated 
in individual semi-structured interviews. 
 
 
1.3 Organisation of Study 
 
Chapter Two outlines the writings, theories and concepts that are considered most 
appropriate to the study area. The chapter reviews the relevant literature pertaining 
to the concepts of addiction and drug treatment together with the elements of a 
comprehensive drug treatment system. It discusses the various pharmacotherapies 
available for opiate detoxification; in particular it reviews the literature in respect of 
the non-opioid 2-adrenergic agonist, lofexidine. It also reviews the substance abuse 
treatment literature to identify patient and treatment process variables that have been 
shown to be important in determining outcome from addiction treatment efforts.  
 
Chapter Three elucidates the research methods, collection and analysis of the data, 
ethical and practical research considerations and limitations of the methods used.  
 
Chapter Four discusses the findings, which have been categorised in line with the 
coding system used in the analysis. The chapter analytically explores the findings, 
making connections and interpretations to the literature review. Finally, Chapter 
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Five outlines the recommendations and conclusion as drawn from the completed 
study. 
 
 
1.4 The Irish Context 
 
According to the Department of Health & Children (1991) ‘of its nature, the 
treatment, care and management of the drug misuser does not lend itself to any one 
solution approach’. Thus the provision of services aimed at the achievement of a drug 
free society only, or harm reduction solely, are inappropriate. There is a need to make 
available to the drug misuser a range of possible approaches and the means of access 
to the services most appropriate to his / her immediate needs and capabilities. A 
fundamental consideration in this respect is to ensure that services available are 
attractive and accessible in order to encourage drug misusers to avail of them and to 
motivate them to continue with treatment.  
 
Although many treatment modalities have been used, the pharmacotherapeutic 
approach, using methadone maintenance therapy is the mainstay of treatment in the 
Irish setting (Sinclair et al, 2001). Methadone is the most widespread substitution 
treatment available in the European Union. Despite the dominance of methadone, 
however, its status has been challenged over the last number of years with many 
European countries now providing alternatives to it (EMCDDA, 2000). There are 
certain disadvantages associated with methadone therapy, including (a) the risk of 
fatal respiratory depression in overdose, because of its full agonist properties (b) the 
inconvenience of daily dosing and daily attendance at clinics, which makes it 
unattractive to some patients and (c) the risk of diversion of take-away doses 
(Mattick et al, 1998). Countries such as the United Kingdom (Neeleman et al, 1997) 
and Germany (Heinemann, 1998) have identified a significant problem associated 
with methadone related deaths. 
 
In Ireland there is very little published information that documents clients’ 
satisfaction with treatment services. O’Connor (2002) examined patient satisfaction 
with the pharmaceutical aspect of methadone treatment services provided in Ireland 
between July 1998 and March 1999. According to the author, respondents were 
pleased to have access to treatment services, secure free treatment and experienced 
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improved standard of care. The clients expressed dissatisfaction with several issues. 
According to respondents there was lack of choice with respect to substitution drugs. 
The respondents also reported that the services provided at drug treatment facilities 
were limited with respect to opening hours and social and personal support. The 
respondents also reported problems with exposure to fellow clients that continued to 
use street opiates and attended methadone treatment services 
 
Farrell (1994) identifies that ambivalence to the use of a drug of dependence to treat 
opioid dependence, government restrictions on prescription of methadone, and 
consumer dislike of the protracted nature of methadone withdrawal have culminated 
in the need for non opiate based drug treatment. Also, it is reported that the 
Pharmaceutical Society of Ireland has proposed that the use of non-opioid 
alternatives to methadone (such as lofexidine) should be considered for use in the 
management of opioid dependence in the future (Sinclair et al, 2001). 
 
In April 2001, the Irish Government approved the National Drugs Strategy, 2001-
2008, in which the need to progress towards a more fully integrated and holistic 
treatment service was identified. It goes on to say that the expansion in the range of 
available treatment types is an important component to the attainment of this goal. 
The consultation process for developing the Strategy highlighted that the use of 
methadone may be ‘inhibiting the use of alternative treatment types’ (Department of 
Tourism, Sport and Recreation, 2001). Lofexidine was identified in the Strategy as 
an alternative treatment type that could be considered although it states that ‘as with 
all substitutes, their applicability to the treatment of heroin misuse in an Irish 
context should be rigorously evaluated and closely monitored’. 
 
The National Advisory Committee in Drugs (NACD)3 monitors the developments in 
the whole range of treatment approaches and, as such, became aware of the 
increased interest in the use of non-opiate based approaches to the management of 
withdrawal from opiates such as heroin and methadone. In response the NACD 
commissioned a review to evaluate the usefulness of lofexidine in the overall 
management of opiate dependence syndrome in the Irish setting. According to Dr 
                                                
3 The NACD was established in response to the drug problem by Minister Eoin Ryan TD in July 
2000, to advise the Government on problem drug use in Ireland in relation to prevalence, prevention 
consequences and treatment based on the analysis and interpretation of research findings 
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Desmond Corrigan, NCAD Chairperson, ‘we are confident that the experience of 
using this aid (lofexidine) to withdrawal will be of enormous benefit to those 
wishing to intervene with clients seeking to explore the drug free treatment options 
available to them’ (NACD, 2003). 
 
In light of the aforementioned issues coupled with the fact that the Clondalkin Drug 
Task Force in its consultation process for its Area Action Plan 2001 identified the 
limited capacity of existing detoxification services in the Clondalkin area to respond 
to the need for non-methadone based treatment. It was felt that a review of both the 
literature and key informants’ experiences of lofexidine should be carried out in 
order to identify an appropriate model for community based detoxification. 
 
 
1.5 Irish Drug Policy 
 
Treatment service provision for problem drug misusers in Ireland until the mid-
1980s was centralised, specialist and ideologically tending towards abstinence 
models of intervention. However, in the context of continuing heroin use and its 
accompanying public health risks, all these features of policy and service provision 
changed gradually over the next decade. (Butler, 2002) 
 
The Irish drug scene (which effectively was the Dublin drug scene) had almost no 
heroin and very little intravenous drug use of any kind prior to 1979. Research in the 
1960s and 1970s on the use of illicit drugs in Ireland found only evidence of 
amphetamine (Walsh, 1996), cannabis, and LSD use (Masterson, 1970; Nevin et al, 
1971). Policy responses included the formation of the Garda Drug Squad, the 
establishment of the National Advisory and Treatment Centre for Drug Abuse and 
the enactment of the Misuse of Drugs Act 1977. The National Advisory and 
Treatment Centre for Drug Abuse was established in Jervis Street hospital in 1969. 
Two years later, in 1971, methadone was introduced as a standardised therapeutic 
approach for the treatment of those dependent on opiates. In 1973, the Coolmine 
Therapeutic Community was also established, “derived from the American concept-
based programmes using the experience of former addicts in the provision of highly 
structured residential services” (Butler, 1991). 
 14
 
The drug scene changed dramatically with the beginning in 1979 of what local 
epidemiologists referred to as the `opiate epidemic’ (Dean et al, 1985) involving the 
large-scale use of heroin in areas of socio-economic deprivation in Dublin. This new 
wave of drug use saw the emergence of a ‘needle culture’ for the first time in 
Ireland, as intravenous drug use became the norm. What became clear, with the 
wisdom of hindsight, was that policies and structures that had been set in place in 
the earlier and more innocent days of illicit drug use in Ireland were seriously 
deficient in the face of the problems associated with intravenous heroin use (Butler, 
1991) 
 
In response a number of Government Committees were established to report on the 
drug problem. However, most of the subsequent action focussed on legislative 
changes to reduce the supply of drugs. Little was implemented in the field of 
demand or harm reduction4 and treatment services remained predominately 
abstinence focussed.  
 
The onset of HIV and AIDS in the early 1980’s began to influence the type of 
services being offered to injecting drug misusers. A report of the National Aids 
Strategy Committee (Department of Health, 1992) stated that “all the indications are 
that the majority of people affected at present (by HIV/AIDS) are from deprived 
urban areas and many have experienced social and economic disadvantage. Statistics 
have shown that intravenous drug use is the main source of transmission of the 
virus; 60% of positive tests are drug related.” 
 
The problem was also examined on a geographic basis, highlighting the Dublin 
Inner City area as having particular problems. Recommendations focused on 
establishing satellite clinics that would treat drug misusers for HIV/AIDS in their 
own communities. This corresponded with the Government Drug Strategy 
(Department of Health, 1991) which aimed to establish Community Drug Teams, 
increase greater participation of General Practitioners (GPs) in managing drug 
misusers in their practice, link people into appropriate services through referral and 
use outreach strategies to target drug misusers not in contact with services.   
                                                
4 Harm reduction refers to a set of practical strategies that reduce the negative consequences of drug 
use, incorporating a spectrum of strategies from safer use, to managed use to abstinence 
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The services were primarily involved in harm reduction and HIV prevention through 
the distribution of clean needles and 'works', and the prescription of methadone. 
Action was forced by public health concerns that the fear of infectious disease, then 
found in a defined population, would spread to the general population. Professional 
bodies in contact with drug users on a daily basis exerted power and influence in the 
evolution of policy aimed not at tackling drug addiction but in reducing injecting 
behaviour, associated crime and risk of HIV. Without much debate, Ireland 
experienced an ideological shift from total abstinence (Coolmine Therapeutic 
Model) to harm reduction (methadone maintenance model). Butler (1991, 1996) 
suggests that because the rationale for the shift in policy focus was primarily due to 
fears of HIV transmission from intravenous drug users into the general population, 
rather than a result of a radical ideological shift, not only did changes in service 
provision occur slowly, but they were marked by conflict and ambivalence in 
service delivery. 
 
Despite these measures, by the mid, 1990s, the drug problem particularly in Dublin 
was still growing. The literature identifies a further shift in drug policy that occurred 
at this time. Farrell et al (1996) described this policy shift as a move from a HIV 
generated response to a broader concern about all aspects of drug misuse with a 
particular concern about the links between drug misuse and crime, and community 
safety and community well being. Central to this policy shift was the belief that the 
rate of drug-related crime may be lowered by bringing problematic drug users into 
treatment. Consequently, government policy (and funding) was directed to the 
expansion of treatment service provision. The extent to which heroin use became 
endemic in Dublin and the way in which treatment policy responded may be 
illustrated through a brief reference to the city’s treatment statistics. 
i. In 1979, the Jervis Street clinic treated 55 heroin users; this figure rose to 
213 in 1980 (Butler, 1991). 
ii. In 1990, the newly established Dublin Drug Treatment Reporting System 
(O’Hare & O’Brien, 1992) reported that 2037 opiate users were being treated 
in an expanding treatment system. 
iii. By December 2000, there were 4936 residents of the Eastern Regional 
Health Authority registered for methadone treatment on the central 
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methadone treatment list (Department of Tourism, Sport and Recreation, 
2001). 
 
Since 1996 the Irish Government’s drugs strategy has been underpinned by the 
findings, recommendations and policies established by the two reports of the 
Ministerial Task Force on Measures to Reduce the Demand for Drugs (1996, 1997). 
Since then the overall aim of the Irish Government’s drugs strategy has been to 
provide an effective, integrated response to the problems posed by drug misuse and 
to work in partnership with communities most affected by the drugs problem in 
tackling the issues raised (Moran et al, 2001). Four basic principles underpinned the 
Government's strategy at that time: 
• it is recognised that an effective strategy must encompass a range of 
responses, which not only address the consequences of drug misuse, but also 
attack its causes; 
• the response to the drug problem must take account of the different levels of 
drug misuse, which are being experienced around the country. While illicit 
drug use is a nation-wide phenomenon (particularly the use of drugs such as 
cannabis and ecstasy), heroin abuse, in view of its public health implications 
and close association with crime, is currently seen as the most pressing 
aspect of the problem. A more targeted response is required, therefore, in the 
areas experiencing the highest levels of heroin abuse; 
• the need for all agencies, which have a role in responding to the drug 
problem, to work together so as to ensure that their individual contributions 
form part of an overall coherent and integrated approach; and 
• the need to tap the depth of experience and knowledge which community 
groups and voluntary organisations can bring to a response to the drug 
problem. It is recognised that there is considerable knowledge and 
experience among communities in the areas experiencing the highest levels 
of use. These communities, therefore, must have an opportunity to 
participate in the design and delivery of the response to the problem in their 
areas (Flood, 1999). 
 
New structures were also introduced to direct and co-ordinate drug policy. The 
operational implementation of approaches to drugs issues was devolved from the 
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National Co-ordinating Committee on Drug Abuse to a more structured sectoral 
approach involving: 
• A Cabinet Committee on Social Inclusion – to confer political leadership to 
drugs policy and to resolve inter-organisational barriers to effective 
responses; 
• An Inter-Departmental Group (IDG) – to address policy issues and review 
progress; 
• A National Drugs Strategy Team – to operate on a cross-departmental basis 
and ensure effective coordination, to identify and consider policy issues 
before being referred to the IDG and co-operate with and over see the work 
of the Local Drug Task Forces; and 
• Local Drug Task Forces (LDTF) – were set up in areas identified as having 
the highest levels of drug misuse. The LDTF’s contribute to national drug 
policy aims and objectives by developing and implementing area action 
plans which co-ordinate existing or planned drug services and addresses any 
gaps in those services. The LDTF’s provide a mechanism that enables local 
communities to participate in developing an integrated response to the 
context and consequences of drug misuse in their local area. The 
Government allocated £10 million to support the implementation of over 200 
separate projects in the initial plans which were prepared in 1997. A further 
£15 million was allocated in 2000 to develop updated plans. 
 
A comprehensive review of the National Drug Strategy was initiated by the 
Government in 2000 which resulted in the current National Drug Strategy 2001-
2008. The overall strategic objective for the Strategy is ‘to significantly reduce the 
harm caused to individuals and society by the misuse of drugs through a concerted 
focus on supply reduction, prevention, treatment and research’ (National Drug 
Strategy 2001-2008, 2001)  The new Strategy endorsed the Irish Government's 
existing approach to tackling the drugs issue. The four 'pillars' of the new Strategy - 
supply reduction, prevention, treatment and research - focus on the same four issues 
as in the Government's previous Drugs Strategy highlighted above. One hundred 
individual actions together with key performance indicators were developed under 
the four pillars which are designed to build on the existing approach and drive the 
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new strategy forward. The new National Drugs Strategy, however, seeks to 
strengthen the strategy and sharpen its focus, by: 
• welcoming the Government's positioning of the National Drugs Strategy 
within the wider Social Inclusion policy and the strong commitment to areas 
of disadvantage in the NDP 2000 - 2006. The Review Team recognises that 
the best prospects for communities affected by the drugs problem, in the 
longer term, rest with a Social Inclusion strategy which delivers much 
improved living standards to areas of disadvantage throughout the country; 
and 
• acquiring all state agencies involved in delivering the National Drugs 
Strategy to specify annual targets in terms of outputs and desired outcomes 
for their respective programmes and initiatives. 
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1.6 The Clondalkin Drug Task Force 
 
The Clondalkin Drug Task Force brings together a range of statutory, community 
and voluntary representatives to design and implement an integrated, holistic 
strategy that seeks to address the context and consequences of problem drug use in 
the Clondalkin area. Clondalkin has a population of approximately 55,705, with a 
high percentage of young people, 30.9% under 15 years in 1996 (Clondalkin 
Partnership, 2000). Unemployment for the area lies at 19% compared to a national 
figure of 15%, local authority housing predominates in certain areas, and early 
school leaving presents as a persistent problem (Clondalkin Partnership, 2000).  
 
To date the only estimate of the prevalence of opiate use in Clondalkin can be found 
in a study carried out by Comiskey in 1996. Minimum prevalence estimates of 
opiate use among males aged 15- 24 years by location of residence was identified in 
the study. In Clondalkin, the minimum prevalence estimate for this cohort was 50.2/ 
1000 or 5.02% of the population. Since Clondalkin has a population of 55,705 
(Census, 1996) this would give an estimated population of male drug users aged 15-
24 years as 2,796. Clondalkin was identified as having the third highest estimated 
level of opiate use among this cohort. One must remember that there exists a paucity 
of information on the estimated prevalence of opiate use among other drug using 
populations, such as females, in Clondalkin. 
 
To date the Task Force has developed two Area Action Plans. The first plan ‘1997-
1999’ received an allocation of approximately 1.2 million and supported a total of 
49 projects under the four pillars of Education, Treatment, Supply and Research, 16 
of which have been mainstreamed. The current plan ‘2001 – 2003’ received 1.5 
million. 
 
In developing its second Area Action Plan the Clondalkin Drug Task Force 
undertook a comprehensive needs assessment in relation to the local drug issue. This 
needs assessment used a combination of several quantitative and qualitative data 
collection techniques in order to assess the nature and extent of health and social 
problems associated with drug misuse in the area together with the ability of the 
community to respond to those problems. The UNDCP (2003) describes needs 
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assessment as a systematic exploration of the current status of a single individual or 
a group with drug misuse problems and of the changes that they and others consider 
necessary to improve their health and social status. One of the key issues identified 
during the process was the limited capacity of existing detoxification services to 
respond to the need for non-methadone based treatment. 
 
 
1.7 Summary 
 
Treatment is central to the reduction of the harms incurred by individuals and the 
community from opiate dependence. Irish Drug Policy has played an important role 
in the development and provision of drug treatment services. The 
pharmacotherapeutic approach, using methadone maintenance therapy is the 
mainstay of drug treatment in the Irish setting. A number of issues have arisen in 
recent years which have challenged the status of methadone therapy. These include 
the risk of fatal respiratory depression in overdose, because of its full agonist 
properties together with the risk of diversion of take-away doses. Dissatisfaction has 
also been expressed by service users in the lack of choice with respect to 
substitution drugs. Thus, in recent years there has been a growing interest in and 
demand for non-opiate alternatives to methadone detoxification, such as the 2-
adrenergic agonist lofexidine. The following chapter identifies the main theories and 
concepts relevant to the development of a non-opiate based community 
detoxification team. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
            
 
2.1 Introduction 
 
This chapter examines the literature available on the topic of addiction and drug 
treatment. It discusses the elements of a comprehensive drug treatment system and 
identifies the various pharmacotherapies available for opiate detoxification. In 
particular it reviews the literature on the non-opioid 2-adrenergic agonist, 
lofexidine. It also reviews the substance abuse treatment literature to identify patient 
and treatment process variables that have been shown to be important in determining 
outcome from addiction treatment efforts. 
 
 
2.2 Addiction 
 
Addiction or a dependence syndrome is described as a cluster of physiological, 
behavioural and cognitive phenomena in which the use of a substance or a class of 
substances takes on a much higher priority for a given individual than other 
behaviours that once had greater value (World Health Organisation, 1992). A central 
descriptive characteristic of the dependence syndrome is the desire, often strong and 
sometimes overpowering, to take psychoactive drugs. 
 
According to the WHO (1992), a definite diagnosis of addiction is usually made if 
three or more of the following have been experienced or exhibited at some time 
during the previous year: 
1. A strong desire or sense of compulsion to take the substance. 
2. Difficulties in controlling substance taking behaviour in terms of its onset, 
termination, or levels of use. 
3. A physiological withdrawal state when substance use has ceased or been 
reduced. 
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4. Evidence of tolerance, such that increases of the psychoactive drugs  are 
required in order to achieve effects originally produced by lower doses. 
5. Progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to obtain or 
take the substance or to recover from its effects. 
6. Persisting with substance use despite clear evidence of overtly harmful 
consequences. 
 
According to the UNDCP (2002) the evidence is compelling that, at the present state 
of knowledge, addiction is best considered a chronic relapsing condition. It is true 
that not all cases of addiction are chronic and some who meet diagnostic criteria for 
substance dependence recover completely without treatment. However, many of 
those who develop addiction disorders suffer multiple relapses following treatments 
and are thought to retain a continuing vulnerability to relapse for years or perhaps a 
lifetime. The available research is quite clear on the following points: 
• Education does not correct drug dependence: it is not simply a problem of 
lack of knowledge. 
• Consequences of drug use (e.g. hangovers, loss of job, arrest, etc.) appear to 
be important stimuli leading to entry into drug abuse treatment. 
• Very few addicted individuals are able to profit from a corrections-oriented 
approach by itself. Relapse rates are over 70 per cent from all forms of 
criminal justice interventions. 
• Addiction is not simply a matter of becoming stabilized and getting the drugs 
out of one’s system. Relapse rates following detoxifications are 
approximately the same as those following incarceration. 
 
Based on these findings, drug abuse is best treated by combinations of continuing 
outpatient therapy, medications and monitoring, with the goal of retaining drug 
abusers in that treatment/monitoring regimen to maximise and maintain the full 
benefits of treatment.  
 23
2.3 Social and Economic Costs of Drug Abuse 
 
Problems of substance dependence produce dramatic costs to all societies in terms 
of lost productivity, transmission of infectious diseases, family and social disorder, 
crime and, of course, excessive utilization of health care (UNDCP, 2003). These 
drug-related problems not only reduce the safety and quality of daily life, they are 
also a source of substantial expense. For example, according to results from a study 
released by the Home Office (2002), the annual economic costs of drug abuse in the 
United Kingdom are between £3.7 billion (or US$ 5.6 billion) and £6.8 billion (or 
US$10.3 billion). Most of these costs fall upon the criminal justice system as a result 
of drug-related criminality in the form of organized crime, burglaries and robberies 
and violence. Other social costs are borne by the health system (about £235 million 
(US$338 million) in 2001 on primary care services, accident and emergency 
admissions and drug abuse treatment), the workplace, schools and families (total 
social costs were estimated at £10.9 billion (US$16.5 billion) to £18.8 billion 
(US$28.4 billion)). It is estimated that 99 per cent of the costs are associated with 
problem drug abusers. As the study estimated that there are 280,000 problem drug 
users in the United Kingdom, each problem drug user could cost about £30,000 
(US$45,000) a year. 
 
A review of research by Yates (1999) concluded that “studies are nearly unanimous 
in finding that subsequent to treatment for drug abuse there is a reduction in the 
utilisation of general health care services”. Also, Cartwright et al (1991) reviewed 
research showing that there was a four-to-one return on the investment of tax dollars 
for law abiding citizens for treatment programmes” and “the crime-reduction impact 
estimated here represents only a portion of the potential savings attributable to drug 
abuse treatment”.  
 
Studies to estimate the healthcare or other social costs of drug abuse have not been 
carried out in Ireland. Nor are estimates available on the economic costs to society 
from drug use. Accepting that the “social costs” incurred by drug use can be defined 
and 
interpreted variously, and that no research has been undertaken in Ireland with the 
specific aim of estimating such costs, a number of research findings can be drawn 
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upon to illustrate evidence of significant costs to individuals, families and 
communities as a result of drug use. 
 
As might be expected, this evidence arises primarily from research on a range of 
social problems associated mainly with disadvantaged communities. Numerous 
researchers have documented the perceived negative impact of high levels of drug 
misuse on communities where drug use is concentrated (O’Higgins 1999; Corcoran 
1998). Residents of estates where drug use is concentrated consistently draw 
attention to the destructive effect of drug use and drug trafficking on community 
life. Furthermore, they are acutely aware of the negative way in which their 
community is perceived by outsiders. Mayock (2000), in a qualitative study of drug 
use by young people in a Dublin inner-city community, noted that respondents made 
constant reference to the area’s drug problem. Furthermore, these young people 
expressed resentment of outside representations of their neighbourhood. They were 
particularly critical of the negative effects of disparaging media reports of drug 
problems in their community, which they felt exaggerated the issue. Many clearly 
felt stigmatised by virtue of living in a locality where drug use and associated 
activities are concentrated. 
 
There is relatively little research available pertaining to the consequences of drug 
problems for individual families. For example, there is no available estimate of the 
number of individuals affected by familial drug use. However, the issue of how 
children are affected by drug misuse has emerged as an issue of critical concern. 
Hogan (1997), in an exploratory study of the social and psychological needs of 
children of drug using parents, found that the majority of children whose parent(s) 
were heroin users were experiencing difficulties at school. Key workers interviewed 
for the purpose of the research expressed concern about the quality and consistency 
of care-giving by drug using parents. 
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2.4 Drug Treatment 
 
Treatment can be defined in general terms as the provision of one or more structured 
interventions designed to manage health and other problems as a consequence of 
drug abuse and to improve or maximise personal and social functioning. According 
to the WHOs’ Expert Committee on Drug Dependence (1998), the term “treatment” 
refers to “the process that begins when psychoactive substance abusers come into 
contact with a health provider or any other community service, and may continue 
through a succession of specific interventions until the highest attainable level of 
health and well-being is reached”. O’Brien et al (2000) defines drug treatment as ‘any 
activity which is targeted directly at people who have problems with their drug use 
and which aims to ameliorate the psychological, medical or social state of individuals 
who seek help for their drug problems’.  
 
According to the UNDCP (2002) “treatment and rehabilitation are seen as a 
comprehensive approach to identification, assistance, health care and social 
integration of persons presenting problems caused by any psychoactive substance 
misuse”. The Expert Committee (WHO, 1998) suggests that treatment should have 
three broad objectives: 
1. to reduce dependence on psychoactive substances 
2. to reduce the morbidity and mortality caused by, or associated with, the use 
of psychoactive substances; and 
3. to ensure that users are able to maximise their physical, mental and social 
abilities and their access to services and opportunities, and to achieve full 
social integration. 
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2.4.1 Elements of a Comprehensive Treatment System 
 
Various terms and labels are used to describe treatments and referral and support 
services for drug abuse. These can be grouped under the headings of ‘open access’ 
services and ‘structured treatments’. Figure 1, shown below, gives a schematic 
diagram of the services and care processes involved in a comprehensive drug 
treatment system. 
 
Figure 1: Drug Treatment System and Care Process 
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2.4.1.1 Open Access Services 
 
Open access services are important elements of an integrated treatment response. 
Those services do not provide formal treatment as such, but act as important points 
of first contact for people who have drug-related problems and for those concerned 
about the drug use of another (for example, parents, siblings, spouses and friends). 
They are provided by both statutory and community/ voluntary agencies, and can 
provide the following services: 
• "Drop-in” (that is, non-appointment-based) service for accessing information 
and advice (health care, legal issues, housing, employment, training etc.); 
• Community outreach and advice; blood-borne virus prevention services, 
including education, counselling and syringe and needle exchange; and 
overdose prevention education; 
• Appointment-based general counselling service; 
• Telephone help-lines for anonymous, confidential advice; 
• Onward referral information and advocacy; 
• Self-help groups for individuals and family members (for example, Narcotics 
Anonymous). 
• Family support groups; and  
• General community aftercare and support services. 
 
One cannot overemphasise the importance of open access services. Some drug 
abusers may be reluctant to resort to specialised drug dependence services, and open 
access resources can be a critical place of first contact for them. Specialised open 
access services, play an invaluable role in minimising the adverse consequences of 
drug abuse and as entry points to the treatment system (UNDCP, 2002). Particularly, 
those services that provide information and specific interventions to prevent 
overdose and the acquisition and transmission of blood-borne infection. 
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2.4.1.2 Structured Treatments 
 
Structured treatment characterises services that are based on a formal assessment, 
the development, monitoring and review of individual plans for client care and a 
programme of medical treatment and/or counselling services. Figure 1, shows that 
the main components of structured treatments include: 
• Detoxification - Medical detoxification is the initial and acute stage of drug 
treatment. The main goal of detoxification programmes is to achieve 
withdrawal in as safe and as comfortable a manner as possible. Various 
medications have been shown to be effective in opioid detoxification, 
including true agonists5 such as methadone, partial agonists such as 
buprenorphine and other non-opioid drugs that are called 2-adrenergic 
agonists (lofexidine or clonidine). Detoxification will be discussed in more 
detail later in this chapter. 
 
• Relapse Prevention/ Rehabilitation - The rehabilitation or relapse 
prevention phase of treatment is oriented to the needs of persons who have 
either completed a formal detoxification or who have dependence but no 
formal withdrawal symptoms requiring access to the previous phase of 
treatment. According to the UNDCP (2003) ‘relapse prevention or 
rehabilitation programmes are designed to change the behaviour of clients to 
enable them to regain control of their urge to use substances’. Goals of this 
phase of treatment are to prevent a return to active substance abuse, to assist 
the patient in developing control over urges to abuse drugs and to assist the 
patient in regaining or attaining improved personal health and social 
functioning. 
 
Both psychosocial and pharmacological interventions are involved in this 
phase of treatment. Interventions can include such diverse elements as 
medications for psychiatric disorders; medications to relieve drug craving; 
substitution pharmacotherapies to attract and rehabilitate patients; group and 
individual counselling and therapy sessions to provide insight, guidance and 
                                                
5 An agonist is a drug that is capable of combining with a cell receptor and stimulating or initiates a 
biochemical response similar to the drug of dependence. 
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support for behavioural changes; and participation in peer help groups (e.g. 
Narcotics Anonymous) to provide continued support for abstinence. 
 
• Aftercare - Some structured treatment programmes distinguish a period of 
less intensive treatment after a client has completed the main programme, 
called aftercare. It may be limited to a month or substantially longer after 
treatment has finished, but is based on the intention to provide ongoing 
support to clients at the level required to maintain the earlier benefits and 
goals.  
 
 
2.5 Detoxification 
 
The previous section has established that detoxification (managed opioid 
withdrawal) is an important component of an effective treatment system for opioid 
dependency. Detoxification may be defined as a process of medical care and 
pharmacotherapy that seeks to help the patient achieve abstinence and 
physiologically normal levels of functioning with the minimum of physical and 
emotional discomfort (Margolin et al, 1991). Pharmacotherapy involves the 
administration of a suitable agonist medication, in progressively diminishing 
amounts, to minimize withdrawal discomfort from opioid, barbiturate and 
benzodiazepine dependence, where a characteristic rebound physiological and 
emotional withdrawal syndrome is experienced usually around 8-12 hours following 
the last dose of the drug.  
 
The detoxification phase of treatment is designed for people who experience 
withdrawal symptoms following prolonged abuse of drugs. There is a complex 
range of variables that can potentially influence the course and subjective severity of 
withdrawal, including the type of opioid used, dose taken, duration of use, general 
physical health, and psychological factors, such as the reasons for undertaking 
withdrawal and fear of withdrawal (Frank 1995; Farrell 1994; Preston 1985). 
According to Gossip et al (1991) ‘the aversive nature of opiate withdrawal is a 
considerable barrier to achieving abstinence, and detoxifying without professional 
assistance is often not successful’. Thus assisting people who have become 
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dependent on opiates to safely overcome the period of withdrawal, and pass through 
it with minimal discomfort, would seem to be an important function of treatment 
services, even if they have an orientation towards methadone maintenance 
prescribing (Ward et al, 1998). 
 
Success rates for opiate detoxification are highly variable (Milvey, 1988), and there 
is no consensus on the best approach to take. If used as a treatment entity in its own 
right, detoxification is associated with a high rate of relapse once the “withdrawal” 
period is completed (Mattick et al, 1996). Therefore, it is usually used as part of a 
treatment programme. In those EU countries which have favoured drug free 
treatment (as opposed to substitution treatment) programmes, detoxification is also 
associated with psychosocial/rehabilitation programmes (EMCDDA, 2001; Farrell 
et al, 2000). It may also be used as a first step for other forms of treatment or at the 
end of an extensive period of substitution therapy (Gowing et al, 2001). Managed 
withdrawal, or detoxification, is not in itself a treatment for dependence (Mattick et 
al, 1996). Rates of completion of withdrawal tend to be low, and rates of relapse to 
opioid use following detoxification are high (Broers et al, 2000; Gossop et al, 1989), 
but withdrawal remains a required first step for many forms of longer-term 
treatment (Kleber et al, 1982). It may also represent the end point of an extensive 
period of substitution treatment such as methadone maintenance. As such, the 
availability of managed withdrawal is essential to an effective and comprehensive 
treatment system. 
 
 
2.5.1 Pharmacotherapies 
 
As already mentioned, the evidence suggests that detoxification from illicit heroin 
and other opioids can be facilitated using dose tapered opioid agonists (mainly 
methadone), the partial antagonist buprenorphine and two non-opioid drugs, 
clonidine and lofexidine (both 2-adrenergic agonists). Evaluating the relative 
merits of those medications is hampered by differences in the operation of treatment 
programmes and various measurement issues to do with clinical assessments of 
withdrawal symptom severity. Allowing for this caveat, Gowing et al (2000) 
conducted a Cochrane review of 218 international detoxification studies and 
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calculated mean completion rates for inpatients and outpatients setting opioid 
detoxification of 75 per cent and 35 per cent, respectively, when using methadone 
and 72 per cent and 53 per cent, respectively, when using an 2-adrenergic agonist. 
 
For many years routine procedures for detoxification involved suppression of 
withdrawal with methadone and gradual reduction of the methadone dose (Kleber et 
al, 1982). This approach derived from observations that the withdrawal syndrome 
from methadone was milder, though longer, than that from morphine. Methadone's 
high oral bioavailability, efficacy and long duration of withdrawal relief (24 to 36 
hours) were additional factors that have contributed to it being the main medication 
used in specialist withdrawal programs for most of the past three decades.  
 
Ambivalence to the use of a drug of dependence to treat opioid dependence, 
government restrictions on prescription of methadone, and consumer dislike of the 
protracted nature of methadone withdrawal (Farrell, 1994) have culminated in the 
need for non opiate based detoxification. Discovery of the capacity of the 2 
adrenergic agonist, clonidine, to ameliorate some signs and symptoms of withdrawal 
led to widespread use of this drug as a non-opioid alternative for managing 
withdrawal (Gossop, 1988). One mechanism underlying opioid withdrawal is 
noradrenergic hyperactivity (Gold et al, 1989). The 2 adrenergic agonists act 
centrally to moderate the symptoms of noradrenergic hyperactivity. Alpha2 
adrenergic agonists bind presynaptically to 2-adrenergic receptors located on the 
nerve endings of noradrenergic neurones and reduce the release of noradrenalin, 
which occurs when the inhibitory effects of opiates is removed (Gold et al, 1981). 
The noradrenalin induced withdrawal symptoms, such as chills, abdominal cramps, 
diarrhoea, rhinorrhoea, piloerection, pupil dilatation, lachrymation and yawning are 
suppressed (Akhurst, 1999) 
 
Clonidine, used at the dosage needed to suppress opioid withdrawal syndrome is 
associated with a number of adverse effects (such as hypotension and sedation) and 
therefore patients require close medical supervision (Ward et al, 1998). This has led 
to the investigation of the effectiveness of other 2 adrenergic agonists, such as 
lofexidine, in the management of opioid withdrawal, the aim being to find a drug 
 32
that has clonidine's capacity to ameliorate the signs and symptoms of opioid 
withdrawal, but with fewer side effects. 
 
Gowing et al (2004) conducted a systematic review of 2 adrenergic agonists in the 
management of opioid withdrawal. The focus of the review was to evaluate the 
effectiveness of these agents in this indication relative to other forms of treatment, 
placebo and each other. A total of 68 studies were identified in the data retrieval 
process of which 24 were judged to fulfil the criteria for inclusion in the systematic 
review. Six of the included studies evaluated the use of lofexidine (n = 200 
subjects). See Appendix 1 for a summary of the included studies. 
 
No significant difference in efficacy was detected for treatment regimes based on 
the 2 adrenergic agonists clonidine and lofexidine, and those based on reducing 
doses of methadone over a period of around 10 days, for the management of 
withdrawal from heroin or methadone. Participants stay in treatment longer with 
methadone regimes, have similar or slightly higher rates of completion of 
withdrawal and experience less adverse effects. Lofexidine appeared to cause less 
hypotension than clonidine. Because of this finding and the fact that clonidine and 
lofexidine are equally effective, the reviewers recommend that lofexidine should be 
the preferred option, particularly for withdrawal in an outpatient setting, if an 2-
adrenergic agonist is to be used. 
 
The National Advisory Committee on Drugs (NACD) (2003) commissioned a 
review to evaluate the potential usefulness of lofexidine in the overall management 
of opiate dependence syndrome in an Irish setting. The review concluded that 
lofexidine may be regarded as a useful additional treatment option in the overall 
management of opiate dependence. The results of the review may be summarised as 
follows:  
1. Lofexidine has been evaluated for use in managed opioid withdrawal 
(detoxification) and has been seen to be at least as effective as clonidine and 
reducing doses of methadone, the currently used treatment modalities.  
2. Use of lofexidine was not associated with significant levels of hypotension, 
making it a suitable treatment for use in the outpatient setting. 
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3. It is not possible to make definitive statements about use of lofexidine in 
specific subgroups, but it has been suggested that response is better in 
younger opiate users or those with a shorter history of abuse. It is not 
recommended for use during pregnancy and there is no information on its 
use in this subgroup. 
4. Reports from usage in clinical practice suggest that managed withdrawal 
using lofexidine requires the close involvement of all members of the drug 
treatment team with the patient during treatment and that lofexidine 
detoxification should be followed by further treatment (such as opioid 
antagonist therapy) and counselling to prevent relapse. 
 
 
2.6 Use of Lofexidine in Clinical Practice 
 
2.6.1 United Kingdom 
 
Since being licensed for opiate detoxification in 1992, lofexidine has become widely 
used in the UK (Arkhurst, 1999). It is authorised to relieve symptoms in patients 
undergoing opiate detoxification. Since its launch, usage has increased steadily and 
one report noted that more than 18,000 courses of lofexidine treatment were used in 
the UK in 1998 and this usage was estimated to increase to more than 21,000 in 
1999 (Strang et al, 1999). 
 
The results of a national survey on the efficacy, and safety of lofexidine were 
recently published (Akhurst, 1999; Akhurst, 2000). The survey was conducted under 
the guidelines for company sponsored safety assessment of marketed medicines 
(SAAM). A total of 1,074 questionnaires from 40 randomly chosen drug 
dependency units were completed and available for evaluation. The data set 
comprised 793 males and 270 females. Approximately 43% were taking heroin, 
28% methadone and 20% both. The majority had been dependent on opiates for  5 
years and almost three quarters had either never attempted a supervised 
detoxification before or had a maximum of 2 previous attempts. Detoxification with 
lofexidine was undertaken in the community in 63% cases. The mean starting dose 
used was 0.8mg/day with the majority of patients achieving their maximum dose by 
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day 3. Most patients were titrated to a mean maximum dose of 2.2mg/day although 
doses up to 5.6mg/day were recorded. The mean duration of treatment was 8.9 days 
(range 1-33 days) with a mean of 10 days for those who successfully completed 
treatment. Information on efficacy was available on 686 detoxification episodes, of 
which 342 (49%) were rated as very successful, 261 (38%) as moderately successful 
and 83 (12%) as poor. Follow-up information was not available from all 
questionnaires but 333 patients were reported to be opiate-free for a period ranging 
from 3 days to 3 years and 327 patients were known to have relapsed. Of interest, 
221 questionnaires recorded an improved lifestyle relating to relationships, 
employment and/or health status. 
 
Adverse events were reported in 351/1074 (32.7%) detoxification episodes. 
Commonest events reported were dizziness (8.5%) sedation (6.6%) insomnia (4%) 
and dry mouth (5%). Hypotension was recorded in 7.5% cases and this resulted in 
discontinuation of treatment in 16 cases and reduction in dosage in a further 47 
cases. It is important to note that not all of the treatment units routinely monitored 
blood pressure and pulse rate, but from the data available it was noted that if 
hypotension and/or bradycardia were to occur, this usually happened within the first 
few days.  
 
The study involved a retrospective review of patient files and therefore data 
collection was incomplete for a number of the parameters. In addition the adverse 
events recorded in the files related primarily to symptoms as routine blood testing 
which might have picked up “concealed adverse events” (e.g. liver or renal 
dysfunction) was not undertaken. However, useful information on the general safety 
of lofexidine has been made available from this survey. 
 
The use of lofexidine in 194 patients undergoing 214 opioid detoxifications over a 
24 month period was reviewed by Sheridan et al (1999). Results showed that 81 
patients (37.9%) remained in treatment by day 8 and 52 (24.3%) were considered to 
have completed detoxification. Reasons for non-completion included failure of 
lofexidine to adequately control the withdrawal symptoms, psychosocial problems, 
or expulsion from the programme due to breaches of the treatment protocol (use of 
prohibited drugs or alcohol). Blood pressure was recorded for the first 5 days of 
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treatment. In general, hypotension, when present, occurred early in treatment and 
generally began to return to normal by the fourth day. Of 144 instances of 
hypotension recorded, only 23 resulted in a withholding or reduction of the dose. 
The remainder resolved spontaneously on continuing medication. Other adverse 
events were not recorded routinely but where they were, they consisted most 
commonly of dizziness, drowsiness, lethargy, nausea and vomiting. Although the 
data represent a retrospective review they are still useful in highlighting the practical 
issues involved in the use of lofexidine. They confirm that lofexidine can be used 
safely, even at maximum doses.  
 
Finally, the practical issues of use of lofexidine at primary care level was discussed 
by 3 GPs in a published article (Smith et al, 1998). This report highlighted the need 
to ensure that lofexidine is used as part of an overall treatment plan (including 
counselling, self-help groups as well as other pharmacotherapy modalities such as 
naltrexone6), in order to ensure long-term abstinence. 
 
 
2.6.2 Ireland 
 
Lofexidine is currently not authorised for use in the management of opiate 
withdrawal in Ireland, although it has been used by some inpatient units and 
outpatient clinics on a named-patient basis. The NACD (2003) reviewed the 
availability and, where data was available, treatment outcomes for the use of 
lofexidine in an Irish setting. In Dublin three outpatient treatment centres and one 
inpatient facility were offering lofexidine to clients. Staff at one of the outpatient 
centres recorded and analysed the treatment outcome data from December 2000 to 
December 2002. A total of 84 clients (98 cases) participate in the ten – day 
programme using a maximum dosage of 2.2mg/day. They were primarily heroin 
smokers or users with a relatively small heroin habit (1 to 2 bags per day) with a 
desire to become drug free. Also included were those on an existing methadone 
programme who had reduced down to low doses (less than 20 mls) and wished to 
become drug free. Successful detoxification was achieved if the patient’s urine was 
free of opiates at the end of the programme. Lofexidine was administered in 
                                                
6 Naltrexone is a drug that antagonises the effects of opioid drugs while producing no 
pharmacological effects of its own.  
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conjunction with full medical and counselling support and patients were seen on a 
daily basis (including weekends). Symptomatic medications were also prescribed on 
“as required” basis. After successful detoxification patients were offered Naltrexone 
therapy and counselling to prevent relapse. 
 
The overall success rate for patient attempts was 38% (37/98 attempts). Success was 
highest among those stable on methadone 80% (8/10) and pure heroin smokers 39% 
(13/33). Those patients classifies as unstable on methadone had a very low success 
rate 14% (2/14). Serious problems with hypotension were not reported.  
 
The review also highlighted that: 
• The Lofexidine programme offers patients an important choice in treatment 
options. The only other outpatient detoxification option hitherto available 
was a gradual methadone dose reduction. This type of detoxification option 
has a tendency to lead onto methadone maintenance. 
• Lofexidine is not suitable for all opiate users wishing to undergo managed 
withdrawal. Exclusion criteria include pregnancy or underlying cardiac or 
renal dysfunction and users with serious co-existing psychiatric morbidity. In 
addition, a history of polydrug use or high levels of alcohol consumption 
make successful detoxification less likely.  
• It was felt that the best indicator of success was the patient’s motivation to 
become drug-free. 
• Lofexidine managed withdrawal requires intensive input from all clinic staff, 
(doctor, nurse, pharmacist and counsellor) because of its short duration. 
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2.7 Effective Treatment Components 
 
The UNDCP (2003) carried out a review of the substance abuse treatment literature 
to identify patient and treatment process variables that have been shown to be 
important in determining outcome from addiction treatment efforts. What follows is 
a brief description of the factors identified has having an influence on the outcome 
of treatment efforts. 
 
 
2.7.1 Patient-Related Factors 
 
2.7.1.1 Severity of Substance Use 
 
A variety of studies of treatments in different national contexts have shown that the 
chronicity and severity of patients' substance use patterns have been reliably 
associated with poorer retention in treatment and more rapid relapse to substance 
use following treatment (Rouns-Bryant et al, 1999; George et al, 1999).  
 
 
2.7.1.2 Severity of Psychiatric Problems 
 
International epidemiological population surveys and clinical studies have shown 
that people with substance abuse and dependence disorders are prone to have 
anxiety, affective and anti-social and other personality disorders (UNDCP, 2003). 
Outcome studies of dependent opioid patients suggest that, for most patients, 
psychiatric symptoms improve early on in treatment and that, on average, there are 
sustained reductions in symptom levels over medium- and long term follow-up 
(Bromme et al, 1999). However, a consistent finding across many studies and 
contexts is that severe psychiatric symptoms and disorders at intake to treatment are 
a reliable predictor of dropout and poorer follow-up outcomes (McLellin et al, 
1996). 
 
 38
2.7.1.3 Treatment Readiness and Motivation 
 
According to Simpson et al (1997) patients who report being ready and motivated to 
receive treatment tend to engage more successfully with the therapeutic programme 
and stay in treatment for longer periods of time.  
 
 
2.7.1.4 Employment 
 
Many people with drug abuse problems have enduring difficulties with obtaining 
and retaining paid employment. Employment has been found to predict retention in 
treatment and good outcome (Simpson et al, 1986). For example, in a sample of 
primarily employed, multiple substance abusers entering private inpatient or 
outpatient programmes, McLellan (1994) showed that employment problems were 
one of the most significant predictors of post-treatment substance abuse and other 
aspects of poor health and social functioning. 
 
 
2.7.1.5 Family and Social Supports 
 
Social supports have been widely studied in the drug abuse and dependence field. 
Social support has been conceptualised variously as the availability of relationships 
that are not conflict-producing and supportive of abstinence; and the active 
participation in peer supported treatments such as Narcotics Anonymous (UNDCP, 
2003). Treatment goals may not be reached at all or may attenuate rapidly following 
treatment if the patient's environmental resources are limited. Thus it follows that 
effective treatments for substance abuse look beyond the programme to assist the 
patient in becoming included in society and improving family relationships and 
personal resources (McKay, 1994). 
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2.7.2 Treatment Related Factors 
 
2.7.2.1 Setting of Treatment 
 
Many studies have investigated differences in effectiveness between various forms 
of hospital inpatient and outpatient/day rehabilitation treatments. One such report 
concluded that for most treatment systems, it is likely that patients who have 
sufficient personal and social resources and who present with no serious medical 
complications should be assessed for outpatient/day treatment (Alterman, 1994). 
The UNDCP (2003) have suggested that given the typically high demand for 
residential care, it seems logical to prioritize that setting for those with acute and 
chronic problems who have social stressors and/or environments that are likely to 
interfere with treatment engagement and recovery. 
 
 
2.7.2.2 Treatment Completion and Retention 
 
There is a substantial amount of literature to support the assumption that patients 
who complete treatment will have better outcomes than those who leave 
prematurely. According to the UNDCP (2003) given that most people who are 
studied in drug abuse treatment programmes have chronic and diverse problems, it is 
to be expected that the longer they remain in treatment, the greater the likelihood 
that significant lifestyle improvements will be achieved and consolidated. A 
consistent finding from the United States' national outcome studies is that patients 
who stay for at least three months in residential programmes have superior post-
departure outcomes than patients with shorter stays (Grella, 1999). Staying in 
treatment enables the patient to acquire new skills and to make progress in the 
programme. Toumbourou et al (1998) found that the time spent in treatment was 
related positively to improved outcomes, but the extent or level of therapeutic 
progress attained emerged as a stronger predictor of outcome than simply the time 
spent in treatment. 
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2.7.2.3 Counselling 
 
The UNDCP (2003) identifies that access to regular substance abuse counselling can 
make an important contribution to the engagement and participation of the patient in 
a treatment programme and to its outcome. The positive impact of individual or 
group counselling and attendance at 12-step meetings was observed in one study 
where greater frequency of attendance at counselling and self-help groups were 
associated with higher completion rates and lower risk of relapse over the 
subsequent six months (Fiorentine et al, 1997) 
 
 
2.8 Summary 
 
Lofexidine, a 2 adrenergic agonist acts centrally to suppress the opiate withdrawal 
syndrome. It offers a non-opiate, rapid withdrawal treatment from opiates, without 
the risk of dependency. Lofexidine is seen as the preferred option for the 
management of withdrawal in an out-patient basis, if a 2-adrenergic agonist is to be 
used. Clinical studies carried out in the United Kingdom on the efficacy and safety 
of lofexidine found that the drug can be used safely in a community stetting. In 
general, it has been found to be suitable mainly for younger users with a short 
history of opiate dependence. It is less effective in those who have a long established 
use or a high dosage requirement of opiates. It may also play a role as adjunctive 
therapy at the end of reducing doses of methadone, used for detoxification. 
 
Thus in considering an alternative model for community detoxification, lofexidine 
provides a viable, safe alternative to methadone. The following chapter outlines the 
research methods employed to identify the model for a community detoxification 
team. 
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CHAPTER THREE 
 
RESEARCH METHODOLOGY 
            
 
3.1 Introduction 
 
The aim of this study is to identify an appropriate alternative model for a 
Community Detoxification Team for implementation in Clondalkin, an urban area 
where there are high levels of opiate misuse. This chapter describes and discusses 
the research methods employed to collect and analyse the data in order to achieve 
the aforementioned aim. It also discusses the quality and validity of the research and 
identifies the ethical issues that arose in the data collection, as well as explaining the 
process involved in identifying the key informants and focus group participants. 
 
 
3.2 Research Design & Rationale for its Choice 
 
In contemplating researching the feasibility of developing a Community 
Detoxification Team using lofexidine the researcher identified that it was possible to 
use a qualitative approach. A review of research methodology highlighted the 
multifaceted nature of research, indicating that it is possible and valuable to look at 
something other than quantifiable outcomes whereby research may shed light on the 
processes and outcomes of practice, thus assisting in building knowledge and skills 
(Shaw et al, 2001). 
 
There are many aspects to an individuals experience and point of view and these 
may not all be accounted for in a purely objective and statistical study. It therefore 
seemed appropriate to take a qualitative approach, facilitating a more descriptive and 
contextual account of the key informants’ experiences. As the research is intended to 
be a vehicle for the expression of their experiences in order to identify a model for 
the development of a Community Detoxification Team, the use of qualitative 
methods was considered to be more appropriate, by focusing on their own 
perceptions, meanings and descriptions. (Dey, 1993; Mason, 1996).  
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Another reason for adopting a qualitative approach was the fact that there is no 
theory as such to prove or disprove. The study is more interested in developing a 
position from the data collected from the key informants. The study is an 
exploration of the topic, from which possibly theories or ideas may develop in an 
emergent rather than positivistic way (Dey, 1993: Robson, 1993). This does suggest 
a grounded theory approach, which can be described as “…an approach and set of 
methods for developing theories, concepts and hypotheses direct from the data 
rather than a priori assumptions, other research or existing theoretical frameworks”. 
(Shaw et al, 2001) However, grounded theory in its pure form (Glaser et al, 1967) 
was not adopted, but rather elements were borrowed such as aspects of theoretical 
sampling and coding, in an effort to ground the theory in the data (Scourfield, 2001). 
 
 
3.3 Data Collection 
 
The data collection took the form of two focus groups and ten semi-structured 
interviews. Contact was made with specific experts in Ireland to identify the 
practical issues associated with use of Lofexidine in out patient detoxification. 
Focus group participants were selected from two existing groups from the 
Clondalkin area. One such group, the North Clondalkin Drug Users Forum, was 
used to identify service users’ perceptions. The second group, the Clondalkin 
Community Representative Forum, was used to identify the perspectives of families 
who are living with drug dependency in the home. Thus it can be said that sampling 
was purposive. Mason (1996) defines purposive/theoretical sampling as “…selecting 
groups or categories to study on the basis of their relevance to your research 
questions, your theoretical position and analytical framework, your analytical 
practice, and most importantly the explanation or account which you are 
developing”.  
 
Focus Groups have become widely used to both examine people’s experiences of 
disease and health services and assess health and social needs (Murray et al, 1994). 
Kitzinger (1995) defines focus groups as ‘a form of group interview that capitalises 
on communication between research participants in order to generate data’. 
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Focus groups were used for the following reasons: 
• They do not discriminate against people with literacy difficulties (Kitzenger, 
1995), this was especially relevant to the service user group, a cohort which 
would normally exhibit literacy difficulties an outcome of very low 
educational attainment rates; 
• Group dynamics can stimulate discussion and ideas (Krueger, 1994; Berg, 
1998). 
• Group dynamics can encourage disclosure (Krueger, 1994). 
• Interaction between group participants can be observed (Berg, 1998). 
• The ‘safety in numbers’ factor can encourage the participation of those who 
are wary of an interviewer or those who are anxious about talking (Kitzinger, 
1995) 
• The flexibility afforded by focus groups allows the researcher to select 
participants to reflect the needs of the study (Kitzinger, 1995) 
 
The idea behind the focus group method is that group processes can help people to 
explore and clarify their views in ways that would be less easily accessible in a one 
– to – one interview (Kitzinger, 1995). In order to facilitate this, a number of open 
ended questions were developed by the researcher (see Appendix 2) to encourage 
the research participants to explore the issues of importance to them, in their own 
vocabulary, generating their own questions and pursuing their own priorities. 
 
The focus groups were facilitated by the researcher who was supported by a scribe. 
A video ‘A Turkey’s Conclusion – A Guide to Lofexidine’ was shown at the 
beginning of each focus group to introduce the topic for discussion. The focus 
groups consisted of a set of individuals from the community identified has having an 
investment or expectation in the efficient and effective operation of a treatment 
service. As already mentioned the focus groups were made up of either service users 
or family members from the Clondalkin area. Table 1, shown below, gives a profile 
for the focus group participants. 
 
Table 1: Profile of Participants on Focus Group Interviews 
Focus Group Total Male Female Age Range 
Service User 9 4 5 22 - 30 
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Families 11 4 7 25 - 54 
 
Semi-structured interviews were used so that the process could retain some of the 
flexibility of an unstructured interview allowing issues to arise, while ensuring that 
comparability and comprehensiveness would not be sacrificed. They foster the 
‘appearance of a conversation or discussion’ (Mason, 1996) allowing for an 
informal style, utilising the interaction between interviewer and interviewee, while 
general themes or topics are covered (Mason, 1996). In contrast to questionnaires, 
interviews offer the possibility of modifying one’s line of enquiry, following up 
interesting responses and investigating underlying motives. (Robson, 1993). A 
further benefit to using interviews is that quotes can then be used to represent 
people’s views and experiences rather than relying on the interpretation of the 
researcher (Miller et al, 1997). 
 
The semi-structured interviews were conducted on the basis of a loose structure 
consisting of open ended questions (see Appendix 3) that initially defined the area to 
be explored and from which the interviewer or interviewee diverged in order to 
pursue an idea or response in more detail. Key informants were identified from a 
target population made up of key personnel who had experience in the establishment 
and operation of lofexidine detoxification programmes as well as those who carried 
out research in the area of lofexidine. Two service users were also interviewed. A 
total of ten interviews were carried out. An introductory letter together with a 
sample copy of the semi structured interview questions were forwarded to each 
interview prior to the interviews taking place.  
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The key informants included: 
• Clinical Director of Addiction Services 
• Two Senior Counsellors 
• Rehabilitation Consultant 
• Director Centre of Advanced Clinical Therapeutics 
• Senior Nurse 
• General Practitioner involved with local clinic 
• Community based Drugs Worker 
• Two Service Users 
 
Both focus groups and interviews were tape-recorded and later transcribed by the 
researcher. This meant that as much information as possible was gathered, and the 
researcher could concentrate on the interview and its process without being 
concerned about taking notes of what was being said. Having tapes and transcripts 
enhances the reliability of the analysis, as they can be accessed and examined for 
corroboration of findings and interpretation (Perakyla, 1997).  
 
It also gave the researcher the opportunity to reflect on his own style of interviewing 
and it meant that in listening back on the tapes he could pick up on points that may 
have been lost in the process of the interview. 
 
 
3.4 Analysis 
 
Analysis of the data was a process, which moved through coding or categorization, 
refinement of codes, identification of linkages and patterns, and interpretation, by 
referring to previously developed theories and concepts (Mason, 1996).  
 
The analysis began with a thematic ordering, that came out of the first reading of the 
transcripts, as well as general impressions that had been developed from conducting 
and transcribing the first few interviews. A ‘two-pass’ coding system was used, 
which involves a first reading and application of simple codes followed by the 
second reading where the codes are updated (Kreuger, 1998). As the codes had 
emerged as each transcript was being coded, it was necessary to return to the 
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transcripts a number of times and recode for themes that had not been identified on 
the initial reading. For example, general views in respect of detoxification and the 
need for alternative treatment options were lost in the original coding. This was time 
consuming, but did ensure that consistency was maintained throughout, as all 
transcripts were finally coded for all possible codes. This exercise also highlighted 
what could be missed, if the researcher is not looking for something in particular, or 
is in fact only looking for something in particular. 
 
Through this process of going through the transcripts and coding for the general 
themes more refinement was developed, including what Dey (1993) describes as 
‘splitting and splicing’. This involved refining and combining categories, i.e. 
clarifying the broader categories and joining other categories where appropriate to 
the analysis, so that by the end of this initial categorization the conceptual tools 
required for the analysis had been significantly sharpened.  
 
Returning to the research questions was crucial in keeping focused at this point, as 
the data was raising many possibilities, which were tempting to follow.  
 
The process of coding was simplified and speeded up by the use of the Nud*ist 4 
computer software package (Mason, 1996). It allowed each piece of text to be coded 
for many categories, initially ‘free nodes’ i.e. codes with no hierarchical 
relationship, without the need for endless copying and cutting. It also made it 
possible to quickly retrieve text that had been coded for a particular category, to 
remind the researcher what the code was referring to, so that similar coding for other 
documents could be completed in a consistent manner. Such consistency is essential 
if the findings and interpretations are to be considered methodologically valid and 
reliable (Silverman, 2000; Rudestam et al, 2001).  
 
The possible disadvantages of the use of computer software packages were kept in 
mind. There is sometimes a temptation to consider the codes as variables and begin 
to compare their relationships to each other (Mason, 1996). This was indeed an 
avenue that was followed for a short time. Krueger also warns against using 
software packages to concentrate on counting rather than as an aid in analysis 
(Krueger, 1998). Counting does help to detect patterns and can be used as the 
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starting point for a more reflective interpretation of why these patterns occur. 
(Morgan, 1998) 
 
The researcher must realise that the computer can show ‘where’ and ‘when’ but 
cannot answer the ‘why’ and ‘how’ questions (Morgan, 1998). 
 
Codes were then systematized on a hierarchical basis in an attempt to begin to 
establish causal links (Lewins, 2001). This process of recognising linkages was also 
aided by the use of Nud*ist 4, by allowing the development of related codes i.e. 
Index Tree Nodes. This was the beginning of the process of identifying linkages, as 
the place of a code hierarchically implies a relationship (Gahan & Hannibal, 1998). 
The tree structure of the nodes made this hierarchy easier to work with and visually 
available. 
 
Once the coding was completed, and the process of making linkages begun, patterns 
began to emerge. Possible linkages and patterns were tested by rigorously going 
back to the data to ascertain if they made sense. This initial analysis began the 
process of grounded theory by taking note of patterns which emerge, and reworking 
them to fit emergent patterns. (Fook, 2001). Nud*ist 4 was useful at this stage, as 
retrievals were instantaneous.  
 
In an attempt to visualise the emerging patterns (Dey, 1993) a graph was developed 
that represented the relationships. This proved to be a useful tool for organising, 
thinking about, and presenting the qualitative connections between programme 
implementation and programme impacts.  
 
Once the patterns were established it was possible to begin to interpret and establish 
them as findings. Some of this interpretation came from the data itself in a grounded 
theory way (Shaw et al, 2001) and more of it was related to previously accepted 
theories and concepts, which have been presented in the Literature Review chapter.  
3.5 Validity & Quality of Research 
 
There are no mechanical or ‘easy’ solutions to limit the likelihood that there will be 
errors in qualitative research, however there are various ways of improving validity 
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Respondent validation, or member checking, includes a range of techniques in 
which the investigator’s account is compared with the accounts of those who have 
been investigated in order to establish the level of correspondence between the two 
sets (Pope et al, 1999). The technique employed in this study involved the validation 
of all interview/ focus group transcripts by the research participants prior to being 
analysed by the researcher. Lincoln et al (1985) regard respondent validation as the 
strongest available check on the credibility of the data collected. 
 
Triangulation involves the comparison of results from two or more different 
methods of data collection (for example semi-structured interviews and focus 
groups) or, more simply, from two or more data sources (for example, interviews 
with members of different interest groups) (Pope et al, 1999). Thus to increase the 
reliability of the findings (Mason, 1996), a triangulated approach was used by 
combining results from both focus groups and semi-structured interviews together 
with data from the various interest groups. Therefore, acknowledging that by 
combining several lines of sight, researchers obtain a better, more substantive 
picture of reality; a richer, more complete array of symbols and theoretical concepts; 
and a means of verifying many of these elements. (Berg, 1998) 
 
Many advise the researcher to take a reflective approach to their work (Mason, 
1996; Shaw et al, 2001). Reflexivity takes into account the context and self of the 
researcher (Shaw et al, 2001) thereby making explicit the influences that could 
affect the approach, assumptions and interpretations being made as all research is 
situated in the personal context, and that my interpretations are necessarily made 
through the lens of my own embodied experience.  
 
As a middle class, professional man in his thirties the researcher’s own experiences 
and background are indeed very different to those of both the families and service 
users who participated in the focus groups, and should be acknowledged, so that any 
analysis can stand alone, or at least be considered in this context. This focus on what 
is known as reflexivity (Schon, 1983) and the interaction that occurs between 
researcher and researched is considered in the study and is made possible by the use 
of qualitative methods. 
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The final technique for reducing bias in qualitative research is to ensure that the 
research design explicitly incorporates a wide range of different perspectives so that 
the view point of one group is never presented as if it represents the sole truth about 
any situation (Pope et al, 1999). Thus the perspectives of both service users and 
families as well as the views of service providers and researchers were considered in 
this research. 
 
 
3.6 Limitations 
 
Qualitative research is sometimes considered not ‘scientific’ in the way that some 
quantitative research based on statistical sampling theory and formal methods of 
interviewing may claim to be. The previous section describes the various tools used 
by the researcher to improve the validity of the research.  
 
The study is based on a reasonably small sample size which can make it difficult to 
generalise from the findings to other interest groups not considered in the research. 
Also the issue of proximity may have influenced the data obtained in the research, as 
the researcher was known to a number of the research participants. The use of an 
independent researcher may have gone some way in limiting the influence the 
researcher may have had. 
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3.7 Research Ethics 
 
Great care must be taken in the protection of research participants when using 
qualitative methods. Most qualitative researchers are committed to abide by a set of 
guidelines of professional ethics (Agar 1980; American Anthropological 
Association 1990; Denzin et al, 1994). Three points are basic to these guidelines 
which were implemented when carrying out this study. First, the purpose of the 
research was made explicit to the subjects, in addition, people had the right to 
choose whether or not to participate. Second, the researcher was able to determine 
that no harm could come to the individual study subjects as a result of their 
participation in the research. Third, the researcher was able to ensure that the 
resulting research and publications could be used in such a way that they may bring 
harm to the participants as a group. Central to achieving these goals was the use of 
an informed consent form in which the guidelines of the research and the person’s 
role in it were described (Appendix 4).  
 
 
3.8 Summary 
 
The grounds for taking a qualitative approach in this study are considered and the 
methods employed are explained and their limitations indicated. The validity and 
quality of the study was discussed together with the various tools used. The ethical 
considerations when using qualitative methods were highlighted which included 
informed consent, confidentiality and protection from harm. Each is reflected on in 
relation to the study, along with the safeguards that were put in place to ensure that 
the appropriate standards were met. Finally the methodological approach taken to 
the analysis of the data is explained. In particular the role that the use of the software 
package, Nud*ist 4, played in aiding this process. 
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CHAPTER FOUR 
 
DISCUSSION 
            
 
4.1 Introduction 
 
This chapter outlines the outcomes and main findings from both semi-structured 
interviews and focus groups. The findings have been combined with relevant 
literature to provide a foundation for the development of a community based 
detoxification team. The findings of the study are presented in seven parts reflecting 
key theme areas identified in the analysis. The first deals with detoxification and the 
need for lofexidine, the second with the components of a lofexidine detoxification 
programme, the third with infrastructural requirements, the fourth with matching 
patients to treatment, the fifth with adverse events, the sixth with rehabilitation and 
the seventh with effective treatment components.  
 
 
4.2 Detoxification 
 
The literature review undertaken identified the high failure rate associated with 
detoxification. The interviews highlighted a number of conflicting views in relation 
to detoxification. Concern was raised by a number of interviewees in relation to the 
inappropriate use of detoxification as a treatment intervention with clients who are 
not ready for detoxification and the negative effect that this can have on the client. 
In essence, setting a client up to fail: 
 
‘…you can instil in somebody a mindset of failure around detoxification if it's used 
inappropriately … I do have some difficulty with the idea of putting somebody on 
detox to be seen to be doing something for them when in your heart of hearts you 
know you're setting the person up to fail, and what that means to somebody's esteem, 
and what that means to somebody being able to eventually achieve abstinence, if 
they've done three or four detox's and they haven't been successful’. EK 
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Another issue which was highlighted regarding detoxification referred to the nature 
of addiction and the fact that people are looking for a quick fix solution to the issue 
that may not be the most appropriate response. 
 
‘…responses in addiction often mirror addictive behaviour in that people need a 
quick fix solution to their problem as they need a quick fix by buying heroin when 
they're strung out, the problem has to be dealt with, has to be sorted out now and 
while they're obviously very motivated now, now is the time to do it and the reality is 
that it may not be the time and you're setting someone up to fail…I think that can be 
quite devastating in some cases’. EK 
 
Others identified that although the detoxification may not be successful, the client 
has had the opportunity to enter a treatment process which has facilitated the 
establishment of contacts with service providers which are necessary for long term 
success. This view was reflected by one interviewee when they commented that: 
 
‘…the contact that's been made between you and them is invaluable, in that we can 
address the individual, we've engaged the family, we've engaged parents, and for 
those who are not successful we can access further supports’. SMD 
 
 
4.2.1 Need for Lofexidine Detoxification 
 
A number of general views identified by the interviewees, which is reflected in the 
literature, demonstrate the need for lofexidine detoxification. These views provide 
an insight into interviewees’ perceptions of lofexidine and the need for the provision 
of alternative treatment options to drug misusers. Both service users and families 
identified the need for more choice in respect of the treatment options available. 
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One service user stated: 
 
‘…I just think that's important that people have choices and families have choices 
and everybody has choices because while it may not resolve the issue of drug use at 
least it's giving people more choice’. Focus Group – Service Users 
 
Those interviewed also referred to the perceived dangers associated with methadone, 
such as the risk of fatal respiratory depression in overdose, because of its full agonist 
properties and the risk of diversion of take-away doses (Mattick et al, 1998). These 
dangers were especially highlighted by families: 
 
‘… a lot of people have difficulties around methadone, you can understand why, 
because there's the resale value, methadone is another drug, you can die from 
overdose on methadone, if you take it with alcohol, all that kind of stuff so I think 
there's a community there that is quite open to looking at this as an alternative to 
methadone’. Focus Group - Families 
 
These views were supported by a number of service providers: 
 
‘…why not offer alternatives that aren't opiate based, that aren't addictive, that can't 
be resold on the street’. DR 
 
Service providers also identified the fact that lofexidine provides another type of 
intervention that can be provided to their clients.  
 
‘It helps me when I work; it enhances my work, gives me another tool in my toolbox, 
because I only had methadone or nothing. Now I have methadone or lofexidine’. 
SMD 
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4.2.2 Methadone versus Lofexidine 
 
No significant difference in efficacy was detected for a treatment regime based on 
the 2 adrenergic agonist lofexidine, and those based on reducing doses of 
methadone, for the management of withdrawal from heroin or methadone. (Gowing 
et al, 2004) Participants stay in treatment longer with methadone regimes, have 
similar or slightly higher rates of completion of withdrawal and experience less 
adverse effects. Service providers were asked to comment on the challenges that 
may arise in terms of managing the client for a lofexidine detoxification as opposed 
to a methadone detoxification. The main issue identified related to the length of 
treatment, interviewees had conflicting views in this issue. One interviewee stated: 
 
‘…methadone would be probably more structured, there’s a specific time that you 
have set out for methadone, the reductions are set out, every body knows what 
they’re doing and their role within it in terms of a professional, the individual 
patient knows from the outset what’s going to happen over the next ten weeks or 
twelve weeks and they have a clear idea of what they’re getting in terms of input. 
Sometimes with Lofexidine because you’re dealing with a much shorter time you 
have to get things moving a little bit more quickly and sort of address things a little 
bit more quickly than you would perhaps given the time structure of methadone 
detox’. EK 
 
Another stated that: 
 
‘…a methadone detox is more challenging because it’s longer…it’s a very long, 
drawn-out process, and in the meantime too many distractions, too many life 
situations can happen, there’s many risks involved. Whereas with Lofexidine it’s a 
ten day detox so if I have my ten days organised, after ten days I have my rehab 
organised. Now all I need for the rehab is clean urine, an opiate free urine. I can 
have that in ten days, and then I can have them go in to rehab’. SMD 
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4.3 Programme Components 
 
A number of protocols have been developed for lofexidine detoxification. All 
service providers that participated in this study were adhering to a 10-day regime 
using 0.2mg lofexidine tablets. Appendix 5 provides the recommended protocol for 
a 10-day lofexidine detoxification. Figure 2, shown on the next page, surmises the 
key programme components identified by the key informants for the 10-day regime.  
 
Blood pressure and pulse are checked daily for at least the first 5 days, and clients 
attended daily at the dispensary during the process. Nursing and counselling staff 
were responsible for brief initial assessments, urinalysis and physiological 
monitoring. 
 
Patients are discouraged from working and driving for the 10-day period: 
 
‘…it's very difficult on them from a physical point of view cause they're trying to 
work against the grain and then emotionally, everything else that goes with 
withdrawing, I would be suggesting that those two weeks are taken off’. AD 
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Figure 2: Components of a 10 – Day Lofexidine Detoxification Regime  
 
 
  
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
Refer to Counsellor for assessment of 
Motivation and Preparation 
 
Refer to G.P. for medical assessment re 
suitability for Lofexidine Detox 
 
Refer to Nurse 
Blood taken for L.F.T.’s FBC, U&E and Viral Screen if 
requested  
Urine analysis and Pregnancy test if necessary 
Baseline B/P and Pulse and advice re: avoidance of postural 
hypotension 
 
Client on methadone 
replacement therapy 
(20 mils methadone) 
External client assessed 
for Treatment 
(smoking heroin – 2 
bags daily) 
See pharmacist daily 
or dispensing and 
monitoring of 
medications. 
See Nurse daily for 
B/P and Pulse 
monitoring 
Refer to counsellor 
during detoxification 
if necessary 
 
Refer to GP; if patient relapses, or becomes hypertensive or 
complains of unusual symptoms during detoxification 
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All patients had open access to nursing, pharmacy, counselling or general 
practitioner if required. The general view of all service providers in relation to the 
components of the programme can be summarised as follows: 
 
‘…it's very simple really in that the most important part I think is the link in and 
being assessed. Usually either the nurses or the counsellors assess them and if they 
feel they might be suitable for a Lofexidine they bring it up at the waiting list 
meeting’. AD 
 
If it is felt that the patient is suitable for the lofexidine programme a medical 
assessment is carried out by a General Practitioner, and if the client is deemed 
suitable for a lofexidine detoxification they are initiated on the programme. 
 
‘….they usually give three urines and start at the beginning of the week on a 
Monday because some people are much more sensitive to the hypotensive effect of 
lofexidine so if they're going to have some kind of a reaction,  it would usually be by 
the third day. So they start off on a Monday on the lowest dose and build up to the 
highest dose of the tablets to day five and then from day five to day ten you 
gradually come down. And if they happen to be on methadone then you will 
gradually bring down the methadone so that by day five when you're on the 
maximum dose of tablets, you're off the methadone as well’. AD 
 
 
4.3.1 Treatment Duration 
 
The short duration of lofexidine detoxification was identified by a number of 
interviewees as being advantageous. One interviewee suggested: 
 
‘...the detox doesn't last as long as say three months when it's a methadone detox or 
a six week detoxification from methadone and in some ways we can fast track them 
into residential if they're willing’. SMD 
 
While another stated: 
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‘…you can see something happening fairly quickly whereas with the methadone it 
does take longer...you get a chance to plan to make some strategies for the future, 
goals for the future’. EP 
 
 
4.3.2 Ancillary Treatments 
 
Lofexidine does not appear to eliminate withdrawal symptoms completely 
(especially insomnia and lethargy) and ancillary treatments are unusually necessary. 
This was made clear when one service provider stated: 
 
‘…they're written up for other drugs that they might need, say for any tummy 
cramps, aches and pains and they do have difficulties with sleeping so I usually 
would prescribe something which is non-addictive, so you're looking after all the 
side effects as well that they may get’. AD 
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4.4 Infrastructural Requirements 
 
Reports from usage in clinical practice suggest that managed withdrawal using 
lofexidine requires the close involvement of all members of the drug treatment team 
with the patient during treatment. The need for a skilled multi-disciplinary team was 
identified by all those interviewed: 
 
‘…as with all of the treatments in terms of withdrawal, you need huge input from 
your team on a daily basis, so you need the drug support workers, you need the 
doctors to see them, nurses, the community, they need to be minded very carefully’. 
MT   
 
All interviewees identified that the team should include, a general practitioner, nurse 
and counsellor. This is supported by the literature, Carroll et al (2001) identified that 
the minimum infrastructural requirements for lofexidine detoxification are a willing 
prescriber, an interested pharmacist, and a clinically satisfactory means of 
monitoring blood pressure. 
 
‘…your counselor, it's so important, you would need a GP obviously, that there 
would be experience and you would probably need a nurse as well. Then there 
probably will be project workers or outreach workers that are involved in the family 
set up that would have input on a daily basis, would know the social set up and what 
supports they have and that’. AD 
 
Carroll et al (2001) went on to state that as in most other addiction treatments, the 
presence of an experienced counsellor improved both immediate and log term 
outcome. This view was reflected by all those interviewed: 
 
‘…part and parcel of them being in treatment for Lofexidine is that they link in with 
their counsellor and that’s part and parcel of it’. AD 
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Another interviewee stated: 
 
‘…I think if you have counselling built in as part of a program, not issue based 
counselling, but just counselling that will support somebody through the process 
and reaffirm their commitment, and reaffirm their motivation, and allow them to talk 
about how they feel about the process they’re going through’. DR 
 
The nurse was identified by all interviewees as having the key role in providing a 
lofexidine detoxification as they see the patients on a daily basis. One stated: 
 
‘…a nurse would have a good inside understanding of the process of addiction, 
would have worked with an addiction therapist, know the issues which arise, is able 
to see the warning signals which people give off before they fail, before they relapse 
or drop out and to be able to engage with that person, work with that person and 
link that person into the appropriate individuals, be that the doctor, the counsellor 
or some form of rehabilitation support’. EK 
 
While another commented: 
 
‘…I would see the nurse’s role as being very much supportive and networking in 
with the other key parts of the team, the doctor, the pharmacist, or a counsellor’. 
MH 
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4.5 Matching Patients to Treatment 
 
There have been a substantial number of research studies that have attempted to 
“match” particular “kinds” of patient with specific types, modalities or settings of 
treatment. The approach to patient-treatment “matching” that has received the 
greatest attention from substance abuse treatment researchers involves attempting to 
identify the characteristics of individual patients that predict the best response to 
different forms of addiction treatments. In general, the majority of these “patient-to-
treatment” matching studies have not shown robust or generalizable findings 
(Gastfriend et al, 1997). Those interviewed identified the need to pick participants 
very carefully for lofexidine detoxification. 
 
‘…you pick your candidate very carefully for detox and it’s not going to beneficial 
for everybody; but in the ones that it is beneficial, and you get them off and that’s 
fine. They get a chance to get back into society very quickly’. MT 
 
Another approach to matching has been to assess the nature and severity of patients' 
problems at intake and then to “match” the specific and necessary services to the 
particular problems presented at the assessment. This has been called “problem-to-
service” matching. One study (McLellan, 1997) suggest that matching treatment 
services to adjunctive problems can improve outcomes in key areas and may also be 
cost-effective as they reduce the need for subsequent treatment due to relapse. This 
view was reflected in by the majority of those interviewed. The following quote 
surmises the general view held by those interviewed in relation to those patients who 
would benefit most from a lofexidine detoxification: 
 
‘…I think in my experience and looking at the literature who benefits most would be 
individuals who have a relatively short history of opiate misuse, individuals who 
would not have been on methadone previously for detoxification, individuals who 
would have good psycho-social support, ideally living at home with family back up 
and support in that regard. They wouldn't be injectors, which would be another 
thing. So it's the younger, more social smokers of heroin who would benefit most’. 
EK 
4.6 Adverse Effects 
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The literature identifies that the main adverse effects experienced by patients when 
using lofexidine include hypotension, dizziness, drowsiness, lethargy, nausea, dry 
mouth and vomiting (Gowing et al, 2004; Arkhurst, 19999; Arkhurst, 2000; 
Sheridan et al, 1999). Hypotensive effects associated with 2 adrenergic treatment 
occurred much more frequently in the studies than did cessation of treatment 
because of adverse effects. This suggests that hypotension can be adequately 
managed by withholding doses and reducing the dose of medication according to 
blood pressure changes (Goweing et al, 2004). Hypotension was referred to be all 
service providers, one interviewee stated: 
 
‘…hypotension is an issue, although it does not appear to be a major problem in 
practise, you are looking out for it, you are aware of it, you either reduce the dose 
or you miss the next dose because you'll be dosing them a few times a day’. MT 
 
All those interviewed identified that adverse effects can occur, but that the intensity 
or regularity in which it occurs depends on the individual patient. 
 
‘…there’s no great adverse effect in relation to the drug itself, I’ve never heard of 
people coming in, a couple of times maybe, they might have head aches or that but 
there’s no great adverse effects of the drug itself. No one has really come and given 
out that Lofexidine is this, that and the other, and whoever does it’s normally not the 
Lofexidine at all, it’s something, a whole different issue’. MH 
 
The main adverse effect identified by both the service users and service providers 
was that of a reduction in energy levels. 
 
‘...Now the biggest problems - and I try and prepare them for it - is that they will be 
very draggy. They won't have huge energy levels, but they won't be sick - they just 
will not have huge energy’. SMD 
 
Service users had conflicting views on the adverse effects experienced, one service 
user commented that: 
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‘It takes your energy away, that's exactly what it does, it drains you’. Focus Group –
Service Users 
 
While, another stated: 
 
‘It didn't hit me at all what you are saying, not at all, I did see other people and they 
were like that on it, I was running around, it took the edge off and that's all I 
wanted, that's all I expected’. Focus Group –Service Users 
 
It was identified that the multidisciplinary team, particularly the nurse and the 
counsellor, play an important role in reassuring patients, when they experience 
adverse effects. 
 
‘And it's to reassure for confidence, for a nurse or a counsellor to reassure the 
person that this is normal. But what I always say to them is - okay, so you're draggy, 
can you live with that? Yeah they can. It's not a big problem. It's only going to last 
for ten days. They're not going to be like this in ten days time actually. They're going 
through the worst of it now, can you manage it? Yeah I can. Are you in pain? No I'm 
not in pain, it's uncomfortable. Okay, is that bit of discomfort worth being clean for, 
going through a rehab for? Yeah, it is. That sort of motivation, just to win them 
through, that they can do it’. SMD 
 
Another interviewee stated: 
 
‘…Yeah, the main difficulties were psychological and mood swings and 
disorientation, I think that's why the counseling was so important because it actually 
helped people to understand that they weren't going crazy, that what they were 
experiencing was actually a medical if you like reaction and it was something that 
would pass in time’. DR 
 
4.7 Rehabilitation/ Relapse Prevention 
 
Rehabilitation or relapse prevention is appropriate for patients who are no longer 
experiencing the acute physiological or emotional effects of recent substance abuse. 
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Goals of this phase of treatment are to prevent a return to active substance abuse, to 
assist the patient in developing control over urges to abuse drugs and to assist the 
patient in regaining or attaining improved personal health and social functioning. 
 
Withdrawal symptoms, particularly drug craving, may continue to be experienced 
for weeks, and even months after detoxification, and the period of recovery from 
dependence is typically lengthy and influenced by a range of factors, both social and 
treatment related. If used as a treatment entity in its own right, detoxification is 
associated with a high rate of relapse once the ‘withdrawal’ period is completed 
(Mattick et al, 1996). The types of intervention ordered following the acute phase of 
withdrawal to promote recovery and prevent relapse are substantially different to 
those offered in the management of withdrawal and may include psychological and 
lifestyle counselling, support groups and pharmacological and medical treatment 
(Gowing et al, 2003). All of those interviewed including service users and family 
members agreed that it was important that lofexidine was part of an integrated care 
plan for the drug misuser. The views of all interviewees are adequately represented 
by the following statements: 
 
‘...I think if it's part of the bigger care plan, whether that care plan would be going 
back to training or whether it's going back to full time employment, once it's not just 
the case of doing detox for the sake of detox’. Focus Group - Families 
 
‘You definitely need something to link up to after a detox, a counselor or a key 
worker someone to just straighten out your head to get a course or something cause 
you're just going home and sitting around’. Focus Group – Service Users 
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Residential rehabilitation programmes were identified as an important option 
available to drug misusers who have completed a lofexidine detoxification, one 
counsellor described residential rehabilitation as: 
 
 ‘…if a boxer is going into a fight, he goes away and trains and shadow boxes to 
prepare himself for the big fight. So that’s how I look at this. This is shadow boxing; 
this is imitation, what it’s going to be like when you come back here. Give them 
three month’s rehearsal time to build themselves up, they’re getting used to the 
habit of not having a habit, if you like’. SMD 
 
Naltrexone7, an opioid antagonist, was identified in both the literature and by those 
interviewed as an important Pharmacological intervention available to those who 
have completed a lofexidine detoxification. Those interviewed identified that 
Naltrexone is particularly useful for those who do not attend a residential 
rehabilitation programme and remain in the community after detoxification. One 
interviewee stated: 
 
‘…you'd really improve your success rate by using Naltrexone for six to twelve 
months, particularly if they're going to try and continue to live in their community’. 
AD 
 
 
                                                
7 Naltrexone blocks the effects of opioid drugs; it produces no pharmacological effects of its own. 
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4.8 Effective Treatment Components 
 
The patient and treatment process variables identified in the literature review as 
being important in determining outcome from addiction treatment efforts were used 
to inform the analysis of the finding. The following patient and treatment variables 
were identified by those interviewed as being important in determining a positive 
outcome for lofexidine detoxification. 
 
 
4.8.1 Patient-Related Factors 
 
4.8.1.1 Severity of Substance Use 
 
The literature shows that the severity of patients' substance use patterns have been 
reliably associated with poorer retention in treatment and more rapid relapse to 
substance use following treatment (Rouns-Bryant et al, 1999; George et al, 1999). 
As already highlighted, the majority of those interviewed identified that those 
individuals who benefit most from a lofexidine detoxification would have a short 
drug history with low doses of methadone or heroin.  
 
 
4.8.1.2 Severity of Psychiatric Problems 
 
A consistent finding across many studies and contexts is that severe psychiatric 
symptoms and disorders at intake to treatment are a reliable predictor of dropout and 
poorer follow-up outcomes (McLellin et al, 1996). In fact serious personality 
disorder or psychiatric problems are included in the exclusion criteria for lofexidine 
detoxification. 
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4.8.1.3 Treatment Readiness and Motivation 
 
The literature states that patients who report being ready and motivated to receive 
treatment tend to engage more successfully with the therapeutic programme and stay 
in treatment for longer periods of time (Simpson et al, 1997). This view was 
supported by all interviewees. All of those interviewed considered that patients need 
to possess sufficient motivation for detoxification to be successful. Many 
interviewees indicated that they would not consider initiating a patient on a 
lofexidine detoxification unless convinced that the patient’s motivation was 
authentic. One UK based study which looked at the use of lofexidine by Drug 
Dependency Units emphasised the need to select patients who are committed to 
becoming opiate free (Arkhusrt, 1999). A common concern expressed by those 
interviewed was that unless patients were highly motivated to change, the 
detoxification process would be a pointless exercise. 
 
‘…the person who is motivated to detox. That's the whole basis behind it really, and 
that's what we would be looking at here with people coming in, the motivation 
behind it. You can have people who may be using what you may consider initially a 
little bit high and they can do very well because they're actually motivated to detox’. 
MH 
 
‘…the patient has to be motivated, it's probably the most important ingredient, 
motivated to beat the band because it's difficult, it doesn't make coming off 
methadone or heroin easy, it's hard, it eases it a little’. AD 
 
 
4.8.1.4 Family & Social Supports 
 
Interviewees considered that a patient’s environment and social supports can impact 
greatly on their chance of successful detoxification. As discussed in the literature 
review, social supports can be defined as the availability of relationships that are not 
conflict-producing and supportive of the drug misuser. All of those interviewed 
identified that those drug misusers with a stable supportive environment had the 
most positive outcomes. One service provider stated: 
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‘…the whole psycho-social support being good is very important, there's no point in 
trying with somebody who's homeless because it's too chaotic but if somebody is at 
home and the family are supporting them through the process, in the evening time, 
the likelihood is that they're going to be able to achieve success more than 
somebody who doesn't have a good psycho-social background of support’. EK 
 
This view was supported by another service provider, when they stated: 
 
‘…those who are in stable accommodation, families are reasonably stable, have 
supports around - maybe a girlfriend or a boyfriend who is not a drug user or who's 
stable on methadone’. SMD 
 
The families, who participated in focus group discussions, identified a number of 
issues that they felt would be important in enabling them to provide adequate 
support to a drug misuser while participating in a lofexidine detoxification 
programme. These included: 
 
• Information – information regarding lofexidine detoxification was 
identified as an important aspect by families. It was highlighted that families 
needed to know what to expect, when their son/ daughter started a lofexidine 
detoxification. This view was supported by a number of service providers, 
one stated: 
 
‘Sometimes families get nervous because they don’t know what to expect, 
sometimes they feel that their son/ daughter are stoned when they're on it 
when really what's happening is the neuro-adrenalin is not being produced 
by the brain anymore, so they haven't got a huge energy, so they look as 
though they're stoned. So it's preparing families that’s important’. SMD 
 
• Peer Support – the availability of support from other families/ parents who 
have had experience of lofexidine detoxification within their home was also 
identified as being important. One focus group member stated: 
 
 69
‘It's a good idea that as a mother you could ring up another mother or 
father, it would be nice to be able to ask a few questions’. Focus Group – 
Families 
 
While another, stated: 
 
‘I suppose maybe to talk to people that have gone through it as well, a group 
of people who would have gone through it before with their own family’. 
Focus Group - Families 
 
• Family Counselling/ Therapy - it was agreed that the availability of family 
counselling/ therapy would support the rebuilding of relationships within the 
home as well as providing a tool for all involved to explore their attitudes 
and heal ‘old wounds’. One focus group member stated: 
 
‘… the old attitudes from the family are still there when people become drug 
free, the person has actually changed quite a lot within a small amount of 
time and the family need to move with that as well’. Focus Group - Families 
 
While another focus group member felts that family therapy would support 
the re-establishment of trust within the home: 
 
‘…trying to build your trust up to the same as it was before’. Focus Group - 
Families 
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4.8.2 Treatment Related Factors 
 
4.8.2.1 Setting of Treatment 
 
The literature highlighted that for most treatment systems, it is likely that patients 
who have sufficient personal and social resources and who present with no serious 
medical complications should be assessed for outpatient/day treatment (Alterman, 
1994). This view was supported by all service providers, in fact only clients who 
present with adequate personal and social resources in terms of motivation and 
support are considered for a lofexidine detoxification. One interviewee identified 
that people are selected: 
 
 ‘…in relation first of all to level of dependence, the amount of heroin they’re using, 
the age of the individual, the family support, the living arrangements of the 
individual’. EK 
 
 
4.8.2.2 Treatment Completion and Retention 
 
There is a substantial amount of literature to support the assumption that patients 
who complete treatment will have better outcomes than those who leave 
prematurely. Both the literature and those who were interviewed identified that there 
was similar, or slightly less completion rates for lofexidine as opposed to 
methadone, the only available alternative. 
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4.8.2.3 Counselling 
 
The UNDCP (2003) identifies that access to regular substance abuse counselling can 
make an important contribution to the engagement and participation of the patient in 
a treatment programme and to its outcome. Therapeutic involvement (measured by 
rapport between counsellor and patient and the patient's ratings of their commitment 
to treatment and its perceived effectiveness) together with counselling session 
attributes (the number of sessions attended and the number of health and other topics 
discussed) have a direct positive effect on retention in treatment (George et al, 
1999). The availability of counselling during a lofexidine detoxification programme 
was identified as an important component, one senior counsellor stated: 
 
‘…somebody going to do a detox, they're very focussed. This is a big deal to them. 
They are putting their cards on the table with their family or with their girlfriend 
and they're saying to them -I'm going for a detox. It's very serious stuff. So they are 
coming into me, they want support, so it means they're really engaging with me in a 
very focussed way, so it's very important’. SMD 
 
Hser (1995) suggests that programme counsellors who possess strong interpersonal 
skills, are organized in their work, see their clients more frequently, refer clients to 
ancillary services as needed and generally establish a practical and “therapeutic 
alliance” with the patient achieve better outcomes. This view was supported by a 
number of the interviewees, one stated: 
 
‘…human contact can make a huge difference, even if I'm not saying a whole lot, 
just the fact that another human being cares about you, believes in you, and has 
even got plans for you can make a huge difference’. SMD 
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4.9 Summary 
 
This chapter provides an overview of the outcomes and main findings of both the 
semi-structured interviews and focus groups. The findings have been analysed and 
combined with the relevant literature to identify the key processes and 
infrastructural factors to be considered in developing a community based 
detoxification team.  
 
The chapter sets the context by identifying the need for the provision of alternative 
treatment options to drug misusers. The key components of a lofexidine 
detoxification programme were identified together with the relevant infrastructural 
requirements. The chapter concludes with an analysis of the data in order to identify 
the patient and treatment related factors deemed necessary in determining a positive 
outcome from lofexidine detoxification. This analysis is summarised below in Table 
2. 
 
Table 2: Summary of Patient and Treatment Related Factors – Lofexidine 
Detoxification 
 
Patient Related Factors Lofexidine 
Severity of Substance Use It is recommended that entry criteria is limited to 
individuals with a relatively short opiate addiction 
who are on low doses of methadone or are smoking 
and using 2 bags of heroin per day 
Severity of Psychiatric 
Problems 
Individuals identified with serious personality 
disorder or psychiatric problems are excluded from 
the programme. 
Treatment Readiness and 
Motivation 
An assessment of motivation is carried out in the 
initial stages of the referral process 
Employment It is recommended that those employed take the 
detoxification period as leave 
Family and Social Supports Client should have a supportive non-drug using 
partner/ family member and stable accommodation 
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Treatment Related Factors Lofexidine 
Setting of Treatment Lofexidine has been identified as being effective in 
an outpatient basis. 
Treatment Completion and 
Retention 
Completion rates for lofexidine are seen to be the 
same or slightly lower then methadone, the most 
widely used alternative for detoxification. 
Counselling The availability of counselling is seen as a key 
component to the programme 
 
The following chapter incorporates the learning and main findings in order to 
identify an appropriate model, using lofexidine, for a Community Detoxification 
Team to be implementation in Clondalkin, an urban area where there are high levels 
of opiate misuse. 
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CHAPTER FIVE 
 
RECOMMENDATIONS 
___________________________________________________________________
___ 
 
5.1 Introduction 
 
The aim of this study is to identify an appropriate alternative model for a 
Community Detoxification Team for implementation in Clondalkin, an urban area 
where there are high levels of opiate misuse. Its objectives were to: 
 
1. To document the nature and extent of existing non-methadone based 
detoxification services using the 2-adrenergic agonist lofexidine; 
2. To identify a range of models of good practice at local, national and 
international level; 
3. To identify appropriate protocols in which a Community Detoxification 
Team should operate; and 
4. To identify an appropriate operational model for a Community 
Detoxification Team, taking account of the current structure of health care 
delivery in Ireland 
 
These objectives have been met through the use of qualitative research methods, in 
which 20 people participated in two focus groups, while 11 participated in 
individual semi-structured interviews. This chapter outlines the recommendations 
and conclusion as drawn from the completed study. 
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5.2 Implications for Practice 
 
Lofexidine is a central 2 agonist, similar to Clonidine but without the risk of 
hypotension at significantly high doses. Simply said, it suppresses the chemicals 
which produce the acute withdrawal symptoms clients experience when they are 
detoxing from opiates. Both the literature and findings have identified that when 
used in the management of opioid withdrawal, lofexidine is typically administered 
orally, in three or four doses per day, to a maximum of around two milligrams per 
day. The primary clinical advantage for lofexidine is its efficacy and safety for rapid 
opiate detoxification, together with the fact that the drug has little or no abuse 
potential.  
 
Lofexidine has not yet been used in a community setting in Ireland, thus it is 
recommended that a Community Detoxification Team be established on a pilot basis 
for a twelve month period.  
 
 
5.3 Community Detoxification Team Model 
 
In considering the main findings in the previous chapter, it is recommended that the 
community detoxification team be made up of a Co-ordinator, Drugs Worker, Nurse 
and GP. It is envisaged that the Drug Worker will have counselling skills. The team 
and the client will also require the assistance of a support person; typically this 
person will be a partner or family member. Their roles and responsibilities include: 
 
• Community Detoxification Co-ordinator – co-ordinates and manages the 
day to day running of the programme. He/ she will facilitate and develop the 
linkages within the overall team to ensure consistency and continuity of 
detoxification regime; 
 
• Drug Worker - provides information to both the client and the support 
person about the course of the withdrawal process; helps to identify and 
establish goals; provides education more broadly about drugs and drug use 
according to need, visits the client on a daily basis; re-assesses goals and 
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interventions if drug use resumes before the completion of withdrawal, 
provides linkage to post-withdrawal support 
 
• Nurse – assess blood pressure; monitors the effect of medications; and 
contacts GP should any complications arise during withdrawal. 
 
• General Practitioner – The GP carries out a medical assessment of clients’ 
health to assess suitability for lofexidine detoxification, as per agreed 
protocols. He/ She initiates the clients’ detoxification by prescribing both the 
lofexidine and appropriate symptomatic medication. They are also available 
should a client experience any adverse reactions. Conducts diagnostic 
testing, feedback results of testing to clients. Reviews symptomatic 
medication if required.  
 
• Support Person – the support person agrees to provide emotional, and if 
necessary physical support to the client. This may include things such as 
sharing activities to distract from the withdrawal process, or giving massage, 
running baths and lifting and fetching. The support person will often also be 
asked to take responsibility for storing withdrawal medications and 
providing them to the client at the appropriate times. 
 
• Client – the client commits to abstaining from the consumption of un-
prescribed drugs and alcohol for the duration of the withdrawal period.  They 
agree to discuss any drug use lapses with the drug worker, as well as any 
urges to use and difficulties encountered in the withdrawal process. 
 
 
5.4 Community Detoxification Programme 
 
It is proposed that the community detoxification programme will take place over a 
four-week period. The programme will begin with a pre-detoxification phase in 
week one, followed by the medical detoxification in week two and three, and finally 
the post detoxification phase occurs in week four. Figure 3, shown below, outlines 
the proposed integrated care pathway for the Community Detoxification Team. 
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Figure 3: Integrated Care Pathway – Community Detoxification Team 
Assessment 
Full assessment of opiate misuse problems, including the 
presence and level of dependence; level of motivation, 
identification of other medical, social and mental health 
problems; complications and risk assessment. 
Patient does not 
meet eligibility 
criteria for 
community 
detoxification 
Eligible for community based detoxification 
Pre-Detoxification Phase 
Aims to provide client and support person with clear information about 
the process as well as the specifics about the programme (proposed start 
and finish date, medication plan, visiting times of drugs worker, 
programme components). It is essential that the client is 
psychologically prepared for detoxification and that any anxieties 
have been identified and minimised where possible. Clients are told 
what withdrawal symptoms they might experience and how best they 
Detoxification 
The client attends the clinic daily over a two week period to receive 
their medication and monitor blood pressure, severity of opiate 
withdrawal and the side effects associated with lofexidine. The Drug 
Worker visits the client in the home over the same period to provide 
support and maintain motivation. An educational input is provided in 
the second week  
Unsuccessful 
completion of 
programme 
Post Detoxification Phase 
This phase is limited to one week and 
essentially involves referral of client 
back to referring agents to initiate relapse 
prevention strategies 
Referral 
Establish existence of an overall care plan for client to 
include relapse prevention strategies such as residential 
rehabilitation, structured day programme, support groups 
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5.4.1 Referral 
 
Clients are referred from locally based service providers. At the referral stage it is 
important to focus the client on what they will do after the detoxification, and not 
allow them to see the detoxification process as the "cure" to their dependence. Thus 
it is important to establish the existence of an overall care plan for the client to 
include relapse prevention strategies such as residential rehabilitation, structured day 
programmes or support groups. It is the responsibility of the referral agency to 
ensure that this plan is in place.  
 
During the referral, other significant aspects of the client’s life are reviewed and 
appropriate support is provided by the referral agency where applicable. It may be 
necessary to help the client with benefit or housing problems, in order to help 
stabilise their lives before the community detoxification. It is important at this stage 
to be realistic with the client in terms of attainment of goals. The goal of the 
community detoxification is a short term, specifically focused task of obtaining a 
drug free status. More medium and long term goals are viewed as being part of the 
remit of the referral agency. 
 
 
5.4.2 Assessment 
 
Referrals are assessed in a thorough manner to determine whether they meet the 
strict criteria for receiving the intervention. Table 3, shown on the next page, 
identifies the suggested indicators applied to clients requesting detoxification using 
lofexidine. Note that the negative column does not necessarily exclude a client, it 
means that extra caution should be exercised during the programme. However in the 
case where the client is pregnant lofexidine should not be used in the community. 
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Table 3: Lofexidine Detoxification Indicators 
Positive Indicators Negative Indicators 
Motivation 
Stable accommodation 24 hour support  
Systolic blood pressure 90 hg or above  
Good mental health  
Good physical health  
Unstable/no accommodation (hostel etc.)  
No support/ support from drug user  
Systolic below 90 hg  
Clinical depression. Suicidal  
Poor LFT (Hep. B/C+)/Pregnancy 
 
The initial assessment is conducted by a drug worker. Information is collected on the 
drug and alcohol history of the client, dependency level, state of physical and 
psychological health, and motivation level. The major concern is safety, so the drug 
worker will conduct a risk assessment and look for any contra-indications. If deemed 
suitable the client is referred to the GP for a medical assessment. There are several 
key factors that should be considered in determining suitability. Table 4 identifies 
the inclusion and exclusion criteria that should be considered when assessing a client 
for community detoxification. 
 
Table 4: Inclusion and Exclusion Criteria – Lofexidine Detoxification 
Inclusion Criteria 
• Clients must be well motivated; 
• They must express a clear desire to detoxify and agree to comply with the 
instructions of the community detoxification team; 
• Clients must have a supportive environment; and 
• The client must have no concurrent mental or physical health problems that 
may be exacerbated by the withdrawal process 
Exclusion Criteria 
• Pregnancy 
• High levels of heroin or methadone use including polydrug users 
• Major heart, liver or respiratory problems 
• Serious personality disorder or psychiatric problems 
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5.4.3 Pre-Detoxification Phase 
 
The pre-detoxification phase aims to alleviate any concern the client or support 
person may have and to make practical suggestions as how to support can be given 
or received. Clear information is provided about the process of home detoxification, 
as well as the specifics about the particular detoxification to take place (e.g. 
proposed start and finish date, medication plan, visiting times of the drug worker, 
information about what to do in case of emergency). It is essential that the client is 
psychologically prepared for detoxification and that any anxieties have been 
identified and minimised where possible. Clients are told what withdrawal 
symptoms they might experience and how best they might deal with them. They are 
also talked through what to expect once the detoxification is complete.  
 
 
5.4.4 Detoxification Programme 
 
The medical aspect of the programme will begin in week two using a 10-day 
lofexidine detoxification regime (see Appendix 5 for protocol). The client attends the 
clinic for the first five days to receive their medication and monitor their blood 
pressure. Severity of both opiate withdrawal and the side effects associated with 
lofexidine are also monitored using a rating scale filled in by client and by the 
observation of physical signs (see Appendix 6 for scales). The nurse also determines 
the level of appropriateness of medication. Any medical problems during the 
detoxification are reported immediately to the GP. 
 
The drug worker visits the client in their home during the same period, at a time 
when medication levels are at their highest and clients are experiencing most 
discomfort and psychological difficulties. During the drug worker’s visits, 
motivation is also looked at and worked on, encouragement and support is given to 
the client and the support person. 
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It is envisaged that most service users will start to feel the benefits of the 
detoxification by the end of the first five days. The drug worker visits the home at 
the start of the second week and generally two or three times more that week. The 
client will continue to attend the clinic on a daily basis to receive educational inputs 
on areas such as the process of addiction, power and powerlessness, decision making 
and co-dependence. 
 
 
5.4.5 Post-Detoxification Phase 
 
Contact is made with the initial referral agency to initiate relapse prevention work. 
Although relapse prevention work is initiated during the pre-detoxification phase, 
much of this work is carried out post-detoxification. The relapse prevention program 
is dependent upon the individual’s circumstances. It may include residential 
rehabilitation programmes, structured day programme or support groups 
 
If a detoxification is not completed by a client it is considered as a learning 
experience. If another detoxification is to be considered then assessment will include 
evaluation of changes in behaviour taking into account the previous attempted 
detoxification. 
 
 
5.5 Monitoring and Evaluation 
 
Outcomes of the pilot phase should be assessed in terms of severity of withdrawal 
experienced by the clients, retention in treatment, completion of withdrawal and 
occurrence of adverse effects - in terms of amelioration of the signs and symptoms 
of withdrawal, retention in treatment, capacity to support completion of withdrawal, 
and the occurrence of adverse effects - including lethargy, fatigue, dry mouth and 
hypotensive effects. Also, qualitative data should be collected in respect of both the 
clients' and support persons' views and perceptions of the effectiveness of 
lofexidine. 
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5.6 Recommendations for Research 
 
A paucity of information exists in respect of a number of key areas related to the use 
of lofexidine in the management of opiate withdrawal. A pharmacoeconomic 
analysis is required of the impact of introducing lofexidine as an alternative to 
methadone in the management of opiate withdrawal in Ireland. There are two 
features that characterise pharmacoeconomic analysis. Firstly, it determines both the 
input (costs) and output (consequences) resulting from drug intervention. Second, 
economic analysis concerns itself with choices as resource scarcity necessitates that 
choices must be made. As a result, pharmacoeconomic evaluation is frequently a 
comparative analysis of alternative courses of action (in this case methadone versus 
lofexidine in the management of opiate withdrawal) in terms of their costs and 
consequences.  
 
Comparisons between reducing doses of methadone and lofexidine could be 
improved. The possible introduction of bias through prolonged periods of 
administration of placebo should be avoided, and outcomes should again be assessed 
in terms of severity of withdrawal, retention in treatment, completion of withdrawal 
and occurrence of adverse effects - in terms of amelioration of the signs and 
symptoms of withdrawal, retention in treatment, capacity to support completion of 
withdrawal, and the occurrence of adverse effects - including lethargy, fatigue, dry 
mouth and hypotensive effects.  
 
With the increasing popularity of buprenorphine, and the potential effectiveness of 
this drug in the management of heroin withdrawal (Gowing et al, 2002), further 
comparisons of lofexidine with buprenorphine regimes would be of value. In 
particular it would be of interest to compare lofexidine and buprenorphine in an 
outpatient setting given that both drugs are considered suitable for this setting, 
lofexidine because it has less hypotensive effect than clonidine, buprenorphine 
because it has a lower risk of overdose than methadone.  
 
There remains uncertainty as to the nature of withdrawal signs and symptoms that 
are not significantly ameliorated by treatment with alpha2 adrenergic agonists. This 
is a further area of potential investigation, with value lying in exploration of adjunct 
medications to address those symptoms that are of significance to patients. These are 
likely to include sleep disturbances, anxiety and aches and pains, aspects suggested 
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by studies included in this review to be incompletely suppressed by both 2 
adrenergic agonists and reducing doses of methadone. 
 
It would be of interest to directly compare the efficacy of lofexidine in managing 
withdrawal from heroin and withdrawal from methadone. In particular, it would be 
of interest to determine whether outcomes differ for patients withdrawing after a 
prolonged period of methadone maintenance treatment, as opposed to a short period 
of stabilisation on methadone prior to detoxification, or illicit use of methadone. 
Given that people who are dependent on heroin or methadone are likely to also use 
other drugs, particularly benzodiazepines, cocaine and alcohol, it would also be of 
interest to investigate the efficacy of lofexidine when polydrug use is involved. 
 
 
 
 84
5.7 Conclusion 
 
Lofexidine is not an opiate and has no role to play outside the detoxification context, 
and very many injecting opiate misusers will continue to need methadone 
maintenance therapy. Potential clients and community organisations need to 
understand that the product is not something which cures opiate addiction. 
Lofexidine is no wonder drug, but is most useful when used in a planned and 
considered manner. We are now in a position to start providing other treatment 
modules for opiate addiction. The future will offer us the challenge to 
develop/improve the protocols for delivering the drug and to explore the settings in 
which the drug can usefully be prescribed. 
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APPENDIX 1 
Summary of Lofexidine Studies included in Cochrane Review “2-adrenergic 
agonists for the management of opioid withdrawal” (Gowing et al, 2004). 
 
Study Type Numbers Doses** Comparator Results 
Bearn et al, 
1996 
 
RCT 
db 
42 Lofex; 
44 Meth; 
on heroin 
+/- meth 
 
Lofex: 0.6mg/d 
increasing by 
0.4mg/d until day 
4; max dose of 
2mg/day 
x3d + tapering 
x3d 
Meth: variable 
start dose  x10d 
“Broadly 
equivalent” 
but more w/d 
symptoms 
with lofex 
early in 
treatment. No 
BP problems 
Bearn et al, 
1998 
 
RCT 22 Lofex (1) 
20 Lofex (2) 
19 Meth; 
on heroin  
+/- meth 
*(All subjects 
stabilised on 
meth prior to 
w/d treatment) 
 
(1) Lofex 
0.6mg/d  to 
2mg/d tapered to 
zero by d10 
(2) Lofex 
1.6mg/1d; 
1mg/x3d;  
0.6mg x 1d 
 
Meth variable 
start dose  x10d 
Overall 
similar rates 
of 
completion.  
(1) lofex 
achieved 
earlier 
detoxification. 
No BP 
problems 
Carnwarth et 
al, 1998 
 
RCT 
db 
26 Lofex; 
24 Clon; 
(+10 left trial 
before 
treatment on 
heroin +/ meth 
 
Lofex 0.6mg/d  
to 1.6mg/d 
Then  over 3d to 
zero at d12  
Clon 0.2mg/d  to 
0.8mg/d then   
x 3d to zero at 
d12   
17/26 + 12/24 
completed 
treatment 
(ns). More 
hypotension 
with Clon. 
Howells et al, 
2002 
Unpublished 
at time of 
Cochrane 
review 
 
RCT 
db 
32 Lofex; 
36 Meth; 
(8 who were 
randomised not 
included); 
“opiate-
dependent”  
non-specific 
 
Lofex 0.6mg/d  
X 0.4mg/d to 
2mg/d x3  
0.4mg/d x3 
(10 days) 
Meth 30mg x 1d  
x 5mg every 
second day to 
zero by d10 
No significant 
difference in 
symptoms.  
Kahn  
et al, 1997 
 
RCT 
db 
14 Lofex; 
14 Clon; 
all stabilised on 
meth 
 
Lofex 0.4mg/d  
to 1.8mg/d if 
necessary. 
Tapered to zero 
by d18 
 
Clon 0.2mg/d  to 
0.9mg/d if 
necessary. 
Tapered to zero 
by d18  
No significant 
difference in 
completion 
rates but lofex 
caused less 
hypotension. 
Lin  
Et al, 1997 
RCT 
Db 
 
40 Lofex; 
40 Clon; 
on heroin 
 
Lofex 0.8mg x 1d 
 to max of 
1.6mg/x2d then 
tapered to zero 
Clon 0.3mg x 1d 
 to max of 0.8mg 
x 2d then tapered 
to zero 
No significant 
difference in 
completion 
rates but lofex 
caused less 
hypotension. 
**Lofexidine usually administered in divided daily doses 
Lofex  = Lofexidine     db   =  double blind 
Clon    = Clonidine     w/d =  withdrawl 
Meth   =  Methadone     BP  =   blood pressure 
RCT    =  Randomised Controlled Trial   
APPENDIX 2 
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FOCUS GROUP QUESTIONS 
 
 
1. What do you think about lofexidine detoxification 
 
2. What do you see are the advantages of lofexidine detoxification 
  
3. What do you see are the disadvantages of lofexidine detoxification 
 
4. What supports do you feel are required for: 
• Families 
• Drug Users 
 
 99
APPENDIX 3 
 
SERVICE PROVIDER & SERVICE USER SEMI-STRUCTURED 
INTERVIEW QUESTIONS 
 
1. How many clients have undergone a Lofexidine Detoxification 
 
2. From your experience who do you feel benefits most from Lofexidine 
Detoxification 
 
3. How are clients selected for the programme, is there a clinical policy 
 
4. Can you describe the components of the detoxification programme 
(staffing etc) 
 
5. Were there any additional supports provided or available during the 
detoxification (i.e. external voluntary agencies, key working ) 
 
6. Did the participants experience any difficulties during the programme 
 
7. What challenges does operating a Lofexidine Detoxification programme 
present you as a service provider 
 
8. Did any difficulties arise in terms of managing the client for a 
Lofexidine detoxification as opposed to a methadone detoxification 
 
9. What works well in Lofexidine Detoxification 
 
10. What does not work so well in Lofexidine Detoxification 
 
11. Is cost an issue in providing Lofexidine 
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SERVICE USER SEMI-STRUCTURED INTERVIEW QUESTION 
 
1. Were did you do your Lofexidine detoxification 
 
2. How long did you have to wait for a Lofexidine Detoxification (Was time 
factor important contributor for choosing Lofexidine) 
 
3. What happened while you were waiting (i.e. active use, attend 
counsellor) 
 
4. What sort of waiting time would you think was acceptable to you 
 
5. How long was your Lofexidine detoxification 
 
6. What was involved (i.e. day programme, structure) 
 
7. What additional supports were provided 
 
8. Were they enough, if not what would have helped you 
 
9. What role did your family play, if any? How important was their role? 
 
10. Do you feel it was successful, Why 
 
11. What was good about your Lofexidine Detoxification 
 
12. What was not so good about it 
 
13. Have you had experience of methadone detoxification? 
 
14. How did that experience compare to Lofexidine 
 
15. Which approach benefited you most, why? 
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APPENDIX 4 
 
CONSENT FORM 
 
The Clondalkin Drug Task Force in its consultation process for its Area Action Plan 
2001 identified the limited capacity of existing detoxification services in the 
Clondalkin area to respond to the need for non-methadone based treatment. In 
response the Task Force proposed the establishment of a Home Detoxification Team 
based on a model of good practice identified from other areas 
 
I agree to participate in this study and am aware that all information given in this 
interview will be strictly confidential. My name will only be used on this consent 
form and the identity of each interviewee will only be available to the research staff. 
 
 
 
Signed: _______________________________________ (Interviewee) 
 
 
Signed: ______________________________________ (Interviewer) 
 
 
Date: ___________________ 
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APPENDIX 5 
 
LOFEXIDINE COMMUNITY DETOXIFICATION PROTOCOL 
10-DAY REGIME 
 
Lofexidine Detoxification Protocol 
 
(i) A 10 day detoxification programme using Lofexidine 0.2mg 
tabs/Symptomatic medications  (as below) 
 
(ii) Dispensed daily  
 
(iii) The patient attends the clinic daily to see the Nurse/Counsellor for 
Blood Pressure/Pulse, Respiration Monitoring, Support and Advice. 
 
(iv) A patient is advised to use no drugs (including cannabis/alcohol) and 
to take their last dose of methadone/heroin the day before they start.) 
 
 
Patient Selection 
 
Entry Criteria 
 
• Patients showing a firm intent to become drug free 
• Heroin smokers or users with a relatively short heroin habit and low level of 
use 
• Those who have weaned down to a low level of methadone (20mls) and wish 
to detox  
• Ideally a patient will have a supportive non-drug using partner/family 
member or friend 
• Urines + ve for opiates (+ve for benzo’s, cocaine etc) 
• BP and pulse within normal limits  
Sys. B.P. > 90mm hg 
PR           > .50 
 
 
Exclusion Criteria 
 
• Pregnant 
• Poly drug users or heavy alcohol consumption 
• Serious personality disorders or psychiatric problems 
• Medical Hx  Heart Dx 
    CVA 
    Raised L.F.T.’s 
    Renal failure 
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Dosage & Administration 
 
• This may be increased by increments of 0.2mgs – 0.4mgs per day up to: Max 
of 2.4mgs (12 tablets) per day 
• Duration of 10 days is recommended 
• At the end of treatment dosage should be reduced gradually over 2-4 day 
period 
 
 
Tab Dispensing for 10 days 
 
Day Frequency Tablets 
1 1  1  1 3 
2 2..2..2 6 
3 2..2..3 7 
4 3..3..3 9 
5 3..3..4 10 
6 3..3..4 10 
7 3..2..3 8 
8 2..2..3 7 
9 2..1..2 5 
10 1..1..1 3 
 Total 68 
 
 
Supportive Medications: 
 
• Buscopan 10mgs tds/ Hyoscine (stomach cramps) up to 6 tabs daily 
• Ponstan 500mg tds/ Mefanamic Acid (arthraigia) 
• Zimovane 11 nocte (Hypnotic) 7.5g tabs 
• Lomotil (diarrhoea) 2.5mg – up to 8 daily 
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During Detoxification 
 
• If BP <90/60 then, 
- Stop 
- Withdraw gradually 2-4/7 
- Withhold 
• If BP 30% from baseline or pt develops physical symptoms – omit next dose 
and seek medical advice 
• If HR <55BPM/60BPM – do not proceed/withhold dose 
• If pale/sweaty/faint and BP <90/60HR <55BPM. Call a doctor a.s.a.p 
• If BP diastolic >30mmhg seek medical advice 
• Day 1/2/3 until max. dose reached stay @ clinic min. 2-3 hours 
• Start on a Tuesday 
• Day 1/2/3/4/5 
• Monitor – Bp 10/15/30/60.120 minutes.  H.R as above and SSA card 
• Offer quiet area to sit 
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APPENDIX 6 
 
LOFEXIDINE SIDE EFFECTS SCALE 
 
Name: _________________________  Date: 
_________________________ 
 
 
Rate each symptom using the following scale: 
 
0 = nil  1 = mild  2 = moderate  3 = severe 
 
Day 1 2 3 4 5 6 7 8 9 10 
Dizziness           
Difficulty 
concentrating 
          
Feeling faint           
No energy           
Drowsiness           
Headache           
Dry mouth           
Total score           
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SEVERITY OF OPIATE WITHDRAWAL SCALE 
 
Name: _______________________  Date: 
____________________________ 
 
Rate each symptom using the following scale 
 
0 = nil  1 = mild  2 = moderate  3 = severe 
 
 
Day 1 2 3 4 5 6 7 8 9 10 
Feeling sick           
Stomach cramps           
Muscle spasms           
Feeling cold/gooseflesh           
Sweating           
Heart pounding           
Muscular tension           
Aches & Pains           
Weakness           
Yawning           
Runny eyes           
Difficulty sleeping           
Total score           
 
 
B.P 
 
          
Pulse 
 
          
 
 
 
 
 
 
 
 
